Статті в журналах з теми "410/.92"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 410/.92.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "410/.92".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Meliani, C., G. Post, G. Rondeau, J. Decobert, W. Mouzannar, E. Dutisseuil, and R. Lefèvre. "DC-92 GHz ultra-broadband high gain InP HEMT amplifier with 410 GHz gain-bandwidth product." Electronics Letters 38, no. 20 (2002): 1175. http://dx.doi.org/10.1049/el:20020846.
Повний текст джерела
2
Taco-Vasquez, Sebastian, Miguel Salinas, Herman Murillo, and William Oñate. "Ethanol to high-octane hydrocarbons using HZSM-5 as catalyst." IOP Conference Series: Earth and Environmental Science 1094, no. 1 (September 1, 2022): 012005. http://dx.doi.org/10.1088/1755-1315/1094/1/012005.
Повний текст джерелаАнотація:
Abstract Dehydration and oligomerization of ethanol to hydrocarbons was studied using a packed-bed reactor over HZSM-5 (SiO2/Al2O3=280 mol/mol) zeolite as catalyst. Nine experiments were performed at different temperature and weight hourly space velocity (WHSV) conditions. The experiments were conducted in three levels for both variables (T: 300, 350, and 410 °C) and (WHSV: 1.3, 3.7, and 7.9 h–1). For all the experiments, ethanol was dehydrated to ethylene; however, oligomerization only occurred at WHSV=1.3 h-1, where the yields to liquid hydrocarbons were 15, 25, and 10% at 300, 350, and 410 °C, respectively. The liquid hydrocarbon products were analyzed by copper metal corrosion, gum content, octane number, Reid vapor pressure, gas chromatography, and fractional distillation. The octane number was about 95 in all cases, higher than Ecuador premium gasoline octane number (92). These laboratory-scale findings provide good insights on the ethanol-to-gasoline approach that could be scaled up to the industry.
3
Docksey, Christopher. "Case C-410/92, Johnson v. Chief Adjudication Officer (“Johnson II”), [I994] ECR I-5483." Common Market Law Review 32, Issue 6 (December 1, 1995): 1447–59. http://dx.doi.org/10.54648/cola1995069.
Повний текст джерела
4
Gusrizal, Gusrizal, Endah Sayekti, and Sri Radianti. "Extract of Rhoeo Discolor Leaf as a Reducing and Stabilizing Agent in the Synthesis of Silver Nanoparticles." Molekul 18, no. 3 (November 20, 2023): 450. http://dx.doi.org/10.20884/1.jm.2023.18.3.8249.
Повний текст джерелаАнотація:
Silver nanoparticles (AgNPs) have been synthesized using Rhoeo discolor leaf extract as a reducing and stabilizing agent. AgNPs were synthesized by adding silver nitrate to the extract of Rhoeo discolor and incubating it in a boiling water bath. The change in color of the mixture from clear to yellow indicated AgNPs formation. The synthesized AgNPs were spherical and showed an absorption peak at around 410-420 nm. The size of particles was distributed from 92 to 485 nm with an average size of 176 nm, and the polydispersity index was 0.185. The stability test showed that synthesized AgNPs were stable for three months of storage at ambient temperature. The extract of Rhoeo discolor were responsible for reducing silver ion and stabilizing the synthesized AgNPs.
5
Fatima, Momal, Khadija Nowaira Abdullah, Momina Rahman, Parivash Bangash, Mashal Rasheed, Nayab Shabir, and Neelofer Nishat. "Exposure to second hand smoke: a survey of pregnant women visiting tertiary care hospitals of Peshawar." Journal of Rehman Medical Institute 7, no. 3 (October 8, 2021): 12–15. http://dx.doi.org/10.52442/jrmi.v7i3.355.
Повний текст джерелаАнотація:
Introduction: Second hand smoke (SHS) is reported to cause 890,000 deaths annually worldwide. It is also a known cause of serious complications in pregnancy. The current study intends to fill in some of the knowledge gap for further research & effective public health interventions.
Objective: To estimate the magnitude of exposure to second hand smoke and assess awareness about it among pregnant women visiting four selected tertiary care hospitals of Peshawar.
Materials & Methods: A descriptive cross-sectional study was conducted at four tertiary hospitals of Peshawar from 1st January to 1st March 2018. Non-probability serial sample of 410 pregnant women was taken. A structured questionnaire was used to collect data. Data were analysed for descriptive statistics using SPSS version 22.
Results: A total of 410 pregnant women were included. The mean age was 21 + 4 years; 149 (36.3%) of the total subjects were exposed to SHS, highest frequency (49%) being in age group 26-35 years. Exposure to SHS was highest (39%) among illiterate ladies; 92% of the subjects were exposed to SHS at home, the main source being their husbands (46%); 40.7% of the subjects were aware of the adverse effects of SHS on fetus, younger (p=0.01) & more educated women (p=0.001) being more likely to be aware.
Conclusions: Exposure of pregnant women to second hand smoke is a public health concern in Peshawar, being more likely among younger, less educated, unaware women, and housewives.
6
Escudier, Bernard J., Sergio Bracarda, José Pablo Maroto Rey, Cezary Szczylik, Paul D. Nathan, Sylvie Negrier, Agnese Cattaneo, Claudia Weiss, Camillo Porta, and Viktor Gruenwald. "Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology." Journal of Clinical Oncology 32, no. 4_suppl (February 1, 2014): 410. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.410.
Повний текст джерелаАнотація:
410 Background: Prospectively collected data evaluating therapy for papillary mRCC are limited. RAPTOR (NCT00688753) evaluated the efficacy and safety of EVE as first-line therapy for papillary mRCC. Methods: Eligible pts had histologically confirmed type 1 or 2 papillary mRCC, ECOG PS ≤1, and no previous systemic therapy for mRCC. Central histology review was mandatory. EVE 10 mg/d was given until disease progression or intolerable toxicity. The primary end point was the PFS rate at 6 months assessed per RECIST 1.0 (central review) in the first 44 pts of the per-protocol population (PPFF; lack of centrally confirmed papillary histology was a protocol violation). Secondary end points included PFS, OS, and safety. Sensitivity (per protocol [PP] and ITT populations), supportive (local review), and subgroup (type 1 and 2 histology) analyses were performed. Results: 92 pts enrolled (median age, 60 y; 78% men). Among pts with papillary RCC per local review (99%), 58% had type 2 and 16% had type 1 (25% missing). Central review confirmed papillary histology in 76% of pts, 59% with type 2 and 33% with type 1 (9% missing). Reasons for discrepancies will be presented. Efficacy results are shown (Table). In the safety population (n=92), the most common grade ≥3 AEs were asthenia (11%), anemia (5%), and fatigue (5%). Conclusions: The RAPTOR study showed that EVE was well tolerated by and provided clinical benefit to pts with both type 1 and type 2 papillary mRCC, although both PFS and OS were longer in type 1. These results support further evaluation of EVE for pts with papillary mRCC. Clinical trial information: NCT00688753. [Table: see text]
7
Mosaferi, S., A. Niasari-Naslaji, N. Bahmani, A. A. Gharahdaghi, A. Abarghani, A. Ghanbari, and A. Gerami. "104 COMPARING DIFFERENT LEVELS OF OSMOLALITY OF SUCROSE EXTENDER ON THE VIABILITY OF SPERMATOZOA IN BACTRIAN CAMEL (CAMELUS BACTRIANUS)." Reproduction, Fertility and Development 18, no. 2 (2006): 160. http://dx.doi.org/10.1071/rdv18n2ab104.
Повний текст джерелаАнотація:
Disaccharides have been used as an extender for dromedary camel semen (Bravo et al. 2000 Anim. Reprod. Sci. 62, 173-193). More recently we have investigated the effect of different concentrations of lactose extender on the viability of Bactrian camel spermatozoa (Mosafer et al. 2005 Reprod. Fertil. Dev. 17, 197). Considering the osmolality (316.1 � 1.48 mOsm/kg) and pH (7.4 � 0.03) of Bactrian camel semen (Mosaferi et al. 2005 Theriogenology 63, 92-101), the objective of this study was to investigate the effect of osmolality of sucrose extender on the viability of Bactrian camel spermatozoa. Sucrose at the concentrations of 9, 10, 11, 12, and 13% with osmolalities of 292, 331, 356, 386, and 410 mOsm/kg, respectively, were prepared. All extenders contained 20% egg yolk and antibiotics, with pH adjusted to 6.9. Semen was collected from camels with a sound history of semen quality and fertility (n = 3) using a modified artificial vagina and divided into different treatments after mechanical reduction of semen viscosity (3). Progressive forward motility of spermatozoa was examined at the time of semen collection and at 4, 12, and 24 h after incubation at 4�C. Data were analyzed using the GLM procedure in SAS/STAT after arcsin transformation. At the time of semen dilution, the progressive forward motility of spermatozoa was greater at osmolality of 331 (23%) compared with 292 (1%), 386 (6%), and 410 (3.5%) mOsm/kg (P < 0.05). No progressive forward motility of spermatozoa was noticed after 4 h incubation at 4�C at osmolalities of 292, 386, and 410 mOsm/kg. At this time, a significant decrease (P < 0.05) of progressive forward motility occurred at osmolalities of 331 (4%) and 356 (0.5%) compared with that of the time of dilution. After 12 and 24 h incubation at 4�C, no progressive forward motility of spermatozoa was detected in any of these extenders. In conclusion, 10% sucrose (331 mOsm/kg) at the adjusted pH of 6.9 was the most suitable concentration of this disaccharide for preserving Bactrian camel semen for less than 4 h under chilled conditions.
8
Elahi, A. Salar, and M. Ghoranneviss. "Retraction notice to “Application of the HFCVD technique for growth of nano-rods and nano-crystals” [J. Cryst. Growth 410 (2015) 82–92]." Journal of Crystal Growth 491 (June 2018): 133. http://dx.doi.org/10.1016/j.jcrysgro.2018.04.015.
Повний текст джерела
9
Yamakawa, Michiyo, Keiko Wada, Yuko Goto, Fumi Mizuta, Sachi Koda, Takahiro Uji, and Chisato Nagata. "Associations between coffee consumption and all-cause and cause-specific mortality in a Japanese city: the Takayama study." Public Health Nutrition 22, no. 14 (May 20, 2019): 2561–68. http://dx.doi.org/10.1017/s1368980019000764.
Повний текст джерелаАнотація:
AbstractObjective:Epidemiological studies suggest that coffee consumption is inversely associated with all-cause and cause-specific mortality. Evidence from studies targeting non-white, non-Western populations is still sparse, although coffee is popular and widely consumed in Asian countries.Design:Population-based, prospective cohort study. We used Cox proportional hazards models with adjustment for dietary and lifestyle factors to estimate associations between coffee consumption and all-cause and cause-specific mortality. Dietary intake including coffee consumption was assessed only at baseline using a validated FFQ.Setting:A Japanese city.Participants:Individuals aged 35 years or older without cancer, CHD and stroke at baseline (n 29 079) and followed from 1992 to 2008.Results:From 410 352 person-years, 5339 deaths were identified (mean follow-up = 14·1 years). Coffee consumption was inversely associated with mortality from all causes and CVD among all participants, but not from cancer. Compared with the category of ‘none’, the multivariate hazard ratio (95 % CI) for all-cause mortality was 0·93 (0·86, 1·00) for <1 cup/d, 0·84 (0·76, 0·93) for 1 cup/d and 0·81 (0·71, 0·92) for 2–3 cups/d. The multivariate hazard ratio (95 % CI) for cardiovascular mortality were 0·87 (0·77, 0·99) for <1 cup/d, 0·76 (0·63, 0·92) for 1 cup/d and 0·67 (0·50, 0·89) for 2–3 cups/d. Inverse associations were also observed for mortality from other causes, specifically infectious and digestive diseases.Conclusion:Drinking coffee, even 1 cup/d, was inversely associated with all-cause mortality and mortality from cardiovascular, infectious and digestive diseases.
10
Shaw, P. W., and D. R. Wallis. "Pheromone trap and crop infestation monitoring of mealybug species in Nelson apple orchards." New Zealand Plant Protection 64 (January 8, 2011): 291. http://dx.doi.org/10.30843/nzpp.2011.64.6001.
Повний текст джерелаАнотація:
Potential applications for synthetic sex pheromones for two troublesome mealybug species found in New Zealand Pseudococcus calceolariae (citrophilus) and P longispinus (longtailed) are ongoing The aim of this pilot study was to compare the results of seasonlong pheromone trapping for both species with crop infestation assessments at harvest A total of four traps of each species was monitored in three commercial Nelson orchard blocks between September 2010 and April 2011 Trapping indicated a sharp peak in male citrophilus mealybug flight activity in mid February with a gradual decline thereafter Longtailed mealybug flight activity increased during March and peaked in late April when trapping ceased Higher numbers of citrophilus mealybug males (36764) were trapped than longtailed mealybug (693) At harvest mealybugs were identified on 357 infested fruit and 295 infested leaves to determine mealybug species composition and relative abundance The dominant species was longtailed mealybug identified on 92 of infested fruit Citrophilus and obscure mealybugs (P viburni) were identified on 3 and 5 of infested fruit respectively From the leaf sample 410 longtailed 4 obscure and no citrophilus mealybugs were identified These results indicate pheromone trap catches do not reflect species abundance in the crop Possible reasons for these results are discussed
11
Tarshis, Gary A., Barry M. Miskin, Terry M. Jones, John Champlin, Kevin J. Wingert, Jeanne D. Breen, and Michael J. Brown. "Once-Daily Oral Gatifloxacin versus Oral Levofloxacin in Treatment of Uncomplicated Skin and Soft Tissue Infections: Double-Blind, Multicenter, Randomized Study." Antimicrobial Agents and Chemotherapy 45, no. 8 (August 1, 2001): 2358–62. http://dx.doi.org/10.1128/aac.45.8.2358-2362.2001.
Повний текст джерелаАнотація:
ABSTRACT This was a double-blind, multicenter study in which 410 adults (≥18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days. The study protocol called for four assessments—before and during treatment, at the end of treatment, and posttreatment. Efficacy evaluations included clinical response and bacterial eradication rates. Of 407 treated patients, 202 (108 women, 94 men) received gatifloxacin and 205 (111 women, 94 men) received levofloxacin. For clinically evaluable patients, the cure rates were 91% for gatifloxacin and 84% for levofloxacin (95% confidence interval [CI] for the difference, −2.0 to 15.2%). Clinical cure rates for microbiologically evaluable patients were 93% for gatifloxacin and 88% for levofloxacin (95% CI for the difference, −6.5 to 16.8%). The bacterial eradication rate was 92% for each group, with gatifloxacin eradicating 93% of the methicillin-susceptible Staphylococcus aureus isolates and levofloxacin eradicating 91% of them. Both drugs were well tolerated. Most of the adverse events were mild to moderate, and nausea was the most common adverse event in each treatment arm. Once-daily oral gatifloxacin (400 mg) is clinically efficacious and well tolerated compared with once-daily levofloxacin (500 mg) for the treatment of patients with uncomplicated SSTIs.
12
TOZLU, ELIF, NASIBE TEKİNER, RECEP KOTAN, and SERKAN ÖRTÜCÜ. "Investigation on the biological control of Alternaria alternata." Indian Journal of Agricultural Sciences 88, no. 8 (August 21, 2018): 1241–47. http://dx.doi.org/10.56093/ijas.v88i8.82561.
Повний текст джерелаАнотація:
Alternaria alternata (Fr.) Keissl. which has a wide host range is an important fungal pathogen causing losses in yield in agricultural crops. The chemicals used for controlling this disease are directly toxic to beneficial microorganisms in soil. This study was carried out to determine the antifungal activities of a total 13 candidate bioagent bacterial isolates of Bacillus subtilis (TV-6F, TV-12H, TV-17C and TV 125 A), Bacillus megaterium (TV 87 A and TV 91 C), Bacillus pumilus (TV 67 C), Paenibacillus polymyxa (TV 12E), Pantoea agglomerans (RK 92 and BRT-B), Pseudomonas fluorescens Biotip F (FDG 37), Bacillus thuringiensis subsp. kurstakii (BAB-410) and Bacillus sphaericus GC subgroup D (FD 49) and bioagent fungal isolates of Trichoderma harzianum (ET 4 and ET 14) against two isolates of A. alternata isolated from strawberry and cucumber on petri plate assays. B. pumilus TV 67C (87.63%-65.89%), B. subtilis TV 6F (77.61%-63.11%) and B. megaterium TV 87A (72.93%-68.87%) bacterial isolates were the most effective isolates against pathogenic fungi in in vitro and bioagent fungal isolates ET 4 and ET 14 inhibited pathogenic fungi grown in in vitro respectively 73.87% -83.33% and 55.85% -74.44%, too. Our results indicated that B. subtilis, B. pumilus, B. megaterium and T. harzianum should be tested against A. alternata in field condition.
13
Wall, Terry. "Ash Behaviour during Combustion and Gasification By David H. Scott. IEA Coal Research: London. 1999. ISBN 92-9029-334-9. Member countries: $136. Educational price: $68. Non-member countries: $410." Energy & Fuels 15, no. 2 (March 2001): 502. http://dx.doi.org/10.1021/ef000070r.
Повний текст джерела
14
Dunning, B. E., P. J. Havel, R. C. Veith, and G. J. Taborsky. "Pancreatic and extrapancreatic galanin release during sympathetic neural activation." American Journal of Physiology-Endocrinology and Metabolism 258, no. 3 (March 1, 1990): E436—E444. http://dx.doi.org/10.1152/ajpendo.1990.258.3.e436.
Повний текст джерелаАнотація:
To address the hypothesis that the neutropeptide, galanin, functions as a sympathetic neurotransmitter in the endocrine pancreas, we sought to determine if galanin is released from pancreatic sympathetic nerves during their direct electrical stimulation in halothane-anesthetized dogs. During bilateral thoracic splanchnic nerve stimulation (BTSNS), both peripheral arterial and pancreatic venous levels of galanin-like immunoreactivity (GLIR) increased (delta at 10 min = +92 +/- 31 and +88 +/- 25 fmol/ml, respectively). Systemic infusions of synthetic galanin demonstrated that 1) the increment of arterial GLIR observed during BTSNS was sufficient to modestly restrain basal insulin secretion and 2) only 25% of any given increment of arterial GLIR appears in the pancreatic vein, suggesting that the pancreas extracts galanin, as it does other neurotransmitters. By use of 75% for pancreatic extraction of circulating galanin, it was calculated that pancreatic galanin spillover (output) increased by 410 +/- 110 fmol/min during BTSNS. To reinforce the conclusion that pancreatic sympathetic nerves release galanin, GLIR spillover was next measured during direct local stimulation of the pancreatic sympathetic input produced by electrical stimulation of the mixed autonomic pancreatic nerves (MPNS) in the presence of the ganglionic blocker, hexamethonium. During this local pancreatic sympathetic nerve stimulation, arterial GLIR remained unchanged, but pancreatic venous GLIR increased by 123 +/- 34 fmol/ml. Thus pancreatic GLIR spillover increased by 420 +/- 110 fmol/min during MPNS in the presence of hexamethonium. We conclude that galanin is released from both pancreatic and extrapancreatic sources during sympathetic neural activation in dogs.
15
Hornik, Christoph, Ira Cheifetz, Andrew Lodge, George Ofori-Amanfo, and Awni Al-Subu. "Correlation between Regional Cerebral Saturation and Invasive Cardiac Index Monitoring after Heart Transplantation Surgery." Journal of Pediatric Intensive Care 07, no. 04 (June 11, 2018): 196–200. http://dx.doi.org/10.1055/s-0038-1660788.
Повний текст джерелаАнотація:
AbstractThe present study assessed the correlations between cerebral regional saturation detected by near infrared spectroscopy (NIRS) and cardiac index (CI) measured by pulmonary artery catheter. This was a retrospective cohort study conducted in the cardiac intensive care unit in a tertiary care children's hospital. Patients younger than 18 years of age who underwent heart transplantation and had a pulmonary artery catheter on admission to the pediatric cardiac intensive care unit between January, 2010, and August, 2013, were included. There were no interventions. A total of 10 patients were included with median age of 14 years (range, 7–17). Indications for transplantation were dilated cardiomyopathy (n = 9) and restrictive cardiomyopathy (n = 1). Mixed venous oxygen saturation (SvO2), cerebral regional tissue saturation (rSO2), and CI were recorded hourly for 8 to 92 hours post-transplantation. Spearman's rank correlation coefficient was used to assess correlations between SvO2 and cerebral rSO2 and between CI and cerebral rSO2. A total of 410 data points were collected. Median, 25th and 75th percentiles of cerebral rSO2, CI, and SvO2 were 65% (54–69), 2.9 L/min/m2 (2.2–4.0), and 75% (69–79), respectively. The correlation coefficient between cerebral rSO2 and CI was 0.104 (p = 0.034) and that for cerebral rSO2 and SvO2 was 0.11 (p = 0.029). The correlations between cerebral rSO2 and CI and between cerebral rSO2 and SvO2 were weak. Cerebral rSO2 as detected by NIRS may not be an accurate indicator of CI in critically ill patients.
16
Кіт, Р. Д. "ОСОБЛИВОСТІ ДИФЕРЕНЦІАЦІЇ ДІЯНЬ ПОВ’ЯЗАНИХ ІЗ ВИКРАДЕННЯ, ПРИВЛАСНЕННЯ, ВИМАГАННЯ ВІЙСЬКОВОСЛУЖБОВЦЕМ ВІЙСЬКОВОГО МАЙНА, А ТАКОЖ ЗАВОЛОДІННЯ НИМИ ШЛЯХОМ ШАХРАЙСТВА АБО ЗЛОВЖИВАННЯ СЛУЖБОВИМ СТАНОВИЩЕМ ЗІ СХОЖИМИ ДИСЦИПЛІНАРНИМИ ТА АДМІНІСТРАТИВНИМИ ПРАВОП". Kyiv Law Journal, № 4 (7 лютого 2023): 133–37. http://dx.doi.org/10.32782/klj/2022.4.20.
Повний текст джерелаАнотація:
Стаття присвячена сучасним проблемам, які виникають с приводу викрадення, привласнення, вимагання військовослужбовцем зброї, бойових припасів, вибухових або інших бойових речовин, засобів пересування, військової та спеціальної техніки чи іншого військового майна, а також заволодіння ними шляхом шахрайства або зловживання службовим становищем зі схожими дисциплінарними та адміністративними правопорушеннями. У зв’язку із військовим станом, якій триває майже рік на території України виникають питання, щодо притягнення до відповідальності осіб, які вчиняють розкрадання військового майна використовуючи службове становище задля полегшення та приховування злочинної діяльності, проте законодавець не визначив правила кваліфікації та розмежовування схожих за своєю суттю діянь, що надалі викликають проблеми з притягненні винних до відповідальності. Стаття присвячена нормативно-правовим актам, які б розкрили сутність вказаних суспільних діянь та дали можливість розмежовувати їх за суспільною небезпечністю, а також надали можливість встановлення істотних ознак відповідальність за вчинення ст. 410 КК України «Викрадення, привласнення, вимагання військовослужбовцем зброї, бойових припасів, вибухових або інших бойових речовин, засобів пересування, військової та спеціальної техніки чи іншого військового майна або заволодіння ними шляхом шахрайства, вчинені військовою службовою особою із зловживанням службовим становищем, або повторно, або за попередньою змовою групою осіб, або такі, що заподіяли істотну шкоду та ч. 3 та ч. 4 цієї статті. Приводяться приклади, які б могли сформулювати в подальшому ознаки вказаних діянь і привести у відповідності до Конституції України, а саме ст. 92 п. 22 правила щодо відмежовування відповідальності при вчинені правопорушення. Запропоновано авторський погляд на класифікацію військових кримінальних правопорушень, пов’язаних з привласненням майна. Зроблені пропозиції щодо удосконалення чинного законодавства.
17
Natarajan, Sowmya, and Vijayakumar Ponnusamy. "Classification of Organic and Conventional Vegetables Using Machine Learning: A Case Study of Brinjal, Chili and Tomato." Foods 12, no. 6 (March 9, 2023): 1168. http://dx.doi.org/10.3390/foods12061168.
Повний текст джерелаАнотація:
Growing organic food is becoming a challenging task with increasing demand. Food fraud activity has increased considerably with the increase in population growth. Consumers cannot visually distinguish between conventional and organically grown food products. Spectroscopic methodologies are presented to identify chemicals in food, thereby identifying organic and conventional food. Such spectroscopic techniques are laboratory-based, take more time to produce an outcome, and are costlier. Thus, this research designed a portable, low-cost multispectral sensor system to discriminate between organic and conventional vegetables. The designed multispectral sensor system uses a wavelength range (410 nm–940 nm) that includes three bands, namely visible (VIS), ultraviolet (UV) and near-infrared (NIR) spectra, to enhance the accuracy of detection. Tomato, brinjal and green chili samples are employed for the experiment. The organic and conventional discrimination problem is formulated as a classification problem and solved through random forest (RF) and neural network (NN) models, which achieve 92% and 89% accuracy, respectively. A two-stage enhancement mechanism is proposed to improve accuracy. In the first stage, the fuzzy logic mechanism generates additional feature sets. Ant colony optimization (ACO) algorithm-based parameter tuning and feature selection are employed in the second stage to enhance accuracy further. This two-stage improvement mechanism results in 100% accuracy in discriminating between organic and conventional vegetable samples. The detected adulterant is displayed on a web page through an IoT-developed application module to be accessed from anywhere.
18
Tran, Ben, Hui-Li Wong, Jayesh Desai, Jeanne Tie, Kathryn Maree Field, Suzanne Kosmider, Susie Bae, Shu Fen Wong, and Peter Gibbs. "Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?" Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 410. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.410.
Повний текст джерелаАнотація:
410 Background: In CRC, the tumor associated immune response can manifest as, (1) a good prognostic anti-tumor local (intra-tumoral) inflammatory response; or (2) a poor prognostic tumor promoting systemic inflammatory response. As suggested for renal cancer, the survival advantage associated with primary resection in mCRC patients (pts) might relate to modification of the tumor associated immune response, through reduction in tumor bulk and the resulting reduction in tumor promoting cytokines. We examine if systemic inflammation at diagnosis predicts benefit from primary resection in mCRC. Methods: A prospectively collected multi-disciplinary CRC database was used to explore clinicopathological data from pts diagnosed with de novo mCRC from Jan 2009 to Jul 2012. Evidence of systemic inflammation was defined as serum albumin (SA) <35g/L or neutrophil-lymphocyte ratio (NLR) >4 at diagnosis. Pts with primary resection >42 days from diagnosis were excluded. Survival analyses utilised the Kaplan-Meier method and log-rank test. Results: Of 212 pts diagnosed with mCRC, 154 (72%) had de novo mCRC. 92 (60%) of these underwent primary resection, 62 (40%) had primary left in situ. SA was available in 141 pts, 71 (50%) had SA <35g/L. NLR was available in all pts, 93 (60%) had NLR >4. Primary resection was associated with superior overall survival (OS): median 32.5mo v 8.4mo (HR 0.29, p<0.001). Systemic inflammation was associated with inferior OS using either SA <35g/L (median 8.4mo v 19.8mo, HR 2.54, p<0.001) or NLR >4 (median 16.8 mo v 13.1 mo, HR 1.59, p=0.03). There was no difference in OS advantages associated with primary resection in pts with SA <35g/L (HR 0.25, p<0.001) compared to normal SA (HR 0.28, p<0.001) at diagnosis; a non significant difference was observed for NLR ≤4 (HR 0.15, p<0.001) compared to NLR >4 (HR 0.42, p=0.001). Data regarding resolution of systemic inflammation following primary resection will be presented. Conclusions: Our study confirms the OS benefit from primary resection in mCRC and the adverse prognostic impact of systemic inflammation. Based on our current data, any benefit from primary tumour resection cannot be explained by an impact on the tumor associated immune response.
19
Saeed, Samir H., Andrew J. Sinnamon, Jacques P. Fontaine, Rutika Mehta, Jobelle Joyce Anne Baldonado, Luis R. Pena, Russell F. Palm, Sarah E. Hoffe, Jessica M. Frakes, and Jose Mario Pimiento. "Survival after esophagectomy for metastatic esophageal cancer: Should surgery’s role be reconsidered?" Journal of Clinical Oncology 42, no. 3_suppl (January 20, 2024): 410. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.410.
Повний текст джерелаАнотація:
410 Background: Standard treatment for stage IV esophageal cancer (EC) is systemic therapy, with surgery considered contraindicated. The objective of this study is to assess the impact of surgical resection on outcomes for patients with metastatic EC. Methods: We reviewed our institution’s IRB-approved database of 1334 esophagectomies from 1994 to 2023 and identified 18 patients with distant disease (stage IV) by AJCC8 found prior to or during surgery. Chi-Square, ANOVA, and Kaplan-Meier survival analyses were used to compare demographics, clinical characteristics, and survival from time of surgery in those with metastatic versus non-metastatic EC. Results: Most metastatic patients were male (89%), Caucasian (83%), and had adenocarcinoma (89%). Compared to the non-metastatic cohort, stage IV EC cases were younger (57 vs 63; p=0.03), non-Caucasian (17% vs 6%; p=<0.001), and more likely to get chemotherapy (41% vs 8%; p=0.04) or immunotherapy (23.5% vs 0%; p=0.06), with no difference in gender (89% vs 83%) and receipt of chemoradiotherapy (94% vs 92%). While the difference in intra-operative complication rates was significant (13% vs 2%; p=0.001), both groups had similar rates of post-operative complications ( p=0.95). Non-regional nodal metastasis had the most favorable outcome (mOS NR; median follow-up=14m); while peritoneal/omental disease had the shortest survival (5.2m). Patients receiving surgery more than a year after stage IV diagnosis ( n=6) had better survival than those who either underwent resection within a year after diagnosis ( n=2) or had metastasis identified at time of surgery ( n=8) ( p=0.02). PDL-1 positive and HER2-neu positive tumors also had better outcomes, with neither group reaching median survival. Conclusions: Esophagectomy for highly selected patients with distant disease demonstrates similar post-operative complication rates to locally advanced EC. For stage IV patients, a short interval from diagnosis to surgery is associated with worse survival; however, prolonged diagnosis-to-surgery interval >12m and PDL-1 and HER2-neu positivity demonstrate better outcomes. Surgery’s role in treatment of stage IV EC preferably more than a year after diagnosis of metastasis should be further studied.
20
Salazar-García, Samuel, José de Jesús Velasco-Cárdenas, Raúl Medina-Torres, and José Roberto Gómez-Aguilar. "SELECCIONES DE AGUACATE CON POTENCIAL DE USO COMO PORTAINJERTOS. I. PRENDIMIENTO Y CRECIMIENTO DE INJERTOS." Revista Fitotecnia Mexicana 27, no. 1 (August 3, 2022): 23. http://dx.doi.org/10.35196/rfm.2004.1.23.
Повний текст джерелаАнотація:
Esta investigación se llevó a cabo en un vivero con sombra de 50 % con el objetivo de evaluar el prendimiento y crecimiento de injertos de 39 selecciones de aguacate (Persea americana Mill.), de las cuales 19 son tolerantes a sequía, 11 a salinidad y nueve a la tristeza del aguacate (Phytophthora cinnamomi Rands), así como dos selecciones de chinini (Persea schiedeana Nees) tolerantes a salinidad. Los portainjertos usados fueron originados por semilla de probables híbridos de las razas Antillana x Guatemalteca y desarrollados en suelo migajón arcillo arenoso de buena fertilidad, en recipientes de 6 L de capacidad. Las plantas fueron regadas durante la época seca. Las selecciones se injertaron sobre los portainjertos de semilla mediante “enchapado lateral” en julio de 1999. En total, se hicieron 1549 injertos, de los cuales 747 correspondieron a selecciones tolerantes a sequía, 392 a salinidad y 410 a P. cinnamomi. El prendimiento global de injertos fue 96 %. En las selecciones tolerantes a P. cinnamomi el prendimiento fluctuó de 92 a 100 %, en las tolerantes a sequía de 40 a 100 %, y en las tolerantes a salinidad de 50 a 100 %. Las selecciones de P. schiedeana, S-44 y S-88, tuvieron un prendimiento de injerto de 100 y 50 %, respectivamente. El diámetro del tallo del portainjerto no afectó el prendimiento de los injertos. El alargamiento del tallo de las selecciones de aguacate injertadas mostró diferencias significativas, pero con propósitos de propagación clonal en el vivero, todas las selecciones alcanzaron una altura apropiada (15 a 20 cm) en menos de 90 d después del injerto.
21
Dhadge, Vijaykumar L., Patricia I. Morgado, Filomena Freitas, Maria A. Reis, Ana Azevedo, Raquel Aires-Barros, and A. Cecilia A. Roque. "An extracellular polymer at the interface of magnetic bioseparations." Journal of The Royal Society Interface 11, no. 100 (November 6, 2014): 20140743. http://dx.doi.org/10.1098/rsif.2014.0743.
Повний текст джерелаАнотація:
FucoPol, a fucose-containing extracellular polysaccharide (EPS) produced by bacterium Enterobacter A47 using glycerol as the carbon source, was employed as a coating material for magnetic particles (MPs), which were subsequently functionalized with an artificial ligand for the capture of antibodies. The performance of the modified MPs (MP–EPS-22/8) for antibody purification was investigated using direct magnetic separation alone or combined with an aqueous two-phase system (ATPS) composed of polyethylene glycol (PEG) and dextran. In direct magnetic capturing, and using pure protein solutions of human immunoglobulin G (hIgG) and bovine serum albumin (BSA), MP–EPS-22/8 bound 120 mg hIgG g −1 MPs, whereas with BSA only 10 ± 2 mg BSA g −1 MPs was achieved. The hybrid process combining both the ATPS and magnetic capturing leads to a good performance for partitioning of hIgG in the desired phase as well as recovery by the magnetic separator. The MPs were able to bind 145 mg of hIgG g −1 of particles which is quite high when compared with direct magnetic separation. The theoretical maximum capacity was calculated to be 410 ± 15 mg hIgG adsorbed g −1 MPs with a binding affinity constant of 4.3 × 10 4 M −1 . In multiple extraction steps, the MPs bound 92% of loaded hIgG with a final purity level of 98.5%. The MPs could easily be regenerated, recycled and re-used for five cycles with only minor loss of capacity. FucoPol coating allowed both electrostatic and hydrophobic interactions with the antibody contributing to enhance the specificity for the targeted products.
22
Takoukam Soh, S. D., Saïdou, M. Hosoda, J. E. Ndjana Nkoulou II, N. Akata, O. Bouba, and S. Tokonami. "Natural radioactivity measurements and external dose estimation by car-borne survey in Douala city, Cameroon." Radioprotection 53, no. 4 (October 2018): 255–63. http://dx.doi.org/10.1051/radiopro/2018032.
Повний текст джерелаАнотація:
A car-borne survey was carried out in Douala, the largest city in Cameroon to make a detailed distribution map of the absorbed dose rate in the city, to locate the high natural radiation areas useful later to carry out indoor radon, thoron, and thoron progeny measurements. Gamma-ray dose rates were measured using 3-in × 3-in NaI(Tl) detector. Activity concentrations of238U,232Th and40K in soil from Douala city were determined by two methods: the first, usingin situgamma spectrometry and the second, at the laboratory using a NaI(Tl) detector. A heterogeneous distribution of absorbed dose rates in air was observed on the dose rate distribution map, and varies from 29 to 86 nGy h−1with an average of 50 nGy h−1, lower than the world average value of 59 nGy h−1. The activity concentrations with NaI(Tl) detector varied from 18 to 47 Bq kg−1for238U, 21 to 54 Bq kg−1for232Th, and 10 to 410 Bq kg−1for40K with averages of 29, 38, and 202 Bq kg−1respectively, forin situmeasurements. They vary between 29–98 Bq kg−1for238U, 29–92 Bq kg−1for232Th, and 40 to 79 Bq kg−1for40K, with averages of 60, 57, and 56 Bq kg−1respectively for soil samples collected at Douala III subdivision. The highest value of the annual effective dose forin situmeasurements by car was observed at Ndogbong and was found to be 0.7 mSv y−1, higher than the world average value of 0.5 mSv y−1.
23
Zhou, Yunping, Tao Wang, Shenyong Zhai, Wei Li, and Qiang Meng. "Linoleic acid and breast cancer risk: a meta-analysis." Public Health Nutrition 19, no. 8 (October 5, 2015): 1457–63. http://dx.doi.org/10.1017/s136898001500289x.
Повний текст джерелаАнотація:
AbstractObjectivePrior studies on linoleic acid, the predominant n-6 fatty acid, and breast cancer risk have generated inconsistent results. We performed a meta-analysis to summarize the evidence regarding the relationship of dietary and serum linoleic acid with breast cancer risk.DesignPertinent studies were identified by a search of PubMed and EMBASE. The fixed- or random-effect pooled measure was selected based on between-study heterogeneity.ResultsEight prospective cohort studies and four prospective nested case–control studies, involving 10 410 breast cancer events from 358 955 adult females across different countries, were included in present study. Compared with the lowest level of linoleic acid, the pooled relative risk (RR; 95 % CI) of breast cancer was 0·98 (0·93, 1·04) for the highest level of linoleic acid. The pooled RR (95 % CI) for dietary and serum linoleic acid were 0·99 (0·92, 1·06) and 0·98 (0·88, 1·08), respectively. The RR (95 % CI) of breast cancer was 0·97 (0·91, 1·04), 0·95 (0·85, 1·07), 0·96 (0·86, 1·07), 0·98 (0·87, 1·10) and 0·99 (0·85, 1·14) for linoleic acid intake of 5, 10, 15, 20 and 25 g/d, respectively. The risk of breast cancer decreased by 1 % (RR=0·99; 95 % CI 0·93, 1·05) for every 10 g/d increment in linoleic acid intake.ConclusionsThis meta-analysis indicated that both dietary linoleic acid intake and serum linoleic acid level were associated with decreased risk of breast cancer, although none of the associations were statistically significant. Further investigations are warranted.
24
Stefani, Maria, Grazia Maria Cerbo, Sandra Mallone, and Domenico Di Lallo. "Description of psychiatric outpatient services in the Lazio region in the years 1989-1992." Epidemiologia e Psichiatria Sociale 5, no. 1 (April 1996): 38–45. http://dx.doi.org/10.1017/s1121189x00003924.
Повний текст джерелаАнотація:
RIASSUNTOScopo - Scopo dello studio è quello di descrivere nel tempo l'attività delle strutture ambulatoriali psichiatriche del Lazio. Disegno - Studio descrittivo. Setting - Sono stati analizzati 21 Dipartimenti di Salute Mentale del Lazio nel periodo 1989-92. La fonte dei dati è rappresentata da una scheda riassuntiva mensile dell'attivita dell'ambulatorio. Principali misure utilizzate - Distribuzione di frequenze e tassi di prevalenza ed incidenza. Risultati - La prevalenza e l'incidenza dell'utenza in trattamento aumentano nel periodo considerate Il tasso di prevalenza annuale (per 100.000 residenti) era pari a 900 nel 1989 e 1020 nel 1992, con un incremento del 13% . Il tasso di incidenza annuale è aumentato da 517 nel 1989 a 564 nel 1992, quello di prevalenza di punto da 410 nel 1989 a 540 nel 1992. Il tipo di risposta più frequente data dal servizio è quella di accoglimento e colloquio che rappresenta negli ultimi tre anni circa il 55% del totale delle risposte. Sul totale degli utenti in carico nell'anno, circa il 25% concludono il trattamento; di questi circa il 75% interrompe il trattamento per abbandono. Nel 1992, il 28% dei soggetti conclude il trattamento con diagnosi di psicosi, il 69 % con quella di nevrosi ed il 3% con diagnosi di ritardo mentale (oligofrenia); rimane ancora elevata la quota di trattamenti conclusi con diagnosi sconosciuta. Conclusioni - L'aumento osservato dei tassi di incidenza e prevalenza puo essere determinato da numerosi fattori come l'aumento della domanda espressa, la maggiore efficienza dei servizi, e la migliore sensibilita di notifica del Sistema Informativo. Il fenomeno dei trattamenti interrotti necessita di essere ulteriormente approfondito valutando l'interazione esistente tra modalita terapeutiche e caratteristiche individuali dell'utenza.
25
Karras, Alexandre, Marine Livrozet, Hélène Lazareth, Nicolas Benichou, Jean-Sébastien Hulot, Antoine Fayol, Sophie Chauvet, et al. "Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients." Clinical Journal of the American Society of Nephrology 16, no. 4 (February 23, 2021): 514–21. http://dx.doi.org/10.2215/cjn.09130620.
Повний текст джерелаАнотація:
Background and objectivesKidney involvement is frequent among patients with coronavirus disease 2019 (COVID-19), and occurrence of AKI is associated with higher mortality in this population. The objective of this study was to describe occurrence and significance of proteinuria in this setting.Design, setting, participants & measurements We conducted a single-center retrospective study to describe the characteristic features of proteinuria measured within 48 hours following admission among patients with COVID-19 admitted in a tertiary care hospital in France, and to evaluate its association with initiation of dialysis, intensive care unit admission, and death.ResultsAmong 200 patients with available data, urine protein-creatinine ratio at admission was ≥1 g/g for 84 (42%), although kidney function was normal in most patients, with a median serum creatinine of 0.94 mg/dl (interquartile range, 0.75–1.21). Median urine albumin-creatinine ratio was 110 mg/g (interquartile range, 50–410), with a urine albumin-protein ratio <50% in 92% of patients. Urine retinol binding protein concentrations, available for 85 patients, were ≥0.03 mg/mmol in 62% of patients. Urine protein-creatinine ratio ≥1 g/g was associated with initiation of dialysis (odds ratio, 4.87; 95% confidence interval, 2.03 to 13.0; P<0.001), admission to the intensive care unit (odds ratio, 3.55; 95% confidence interval, 1.93 to 6.71; P<0.001), and death (odds ratio, 3.56; 95% confidence interval, 1.90 to 6.54; P<0.001).ConclusionsProteinuria is very frequent among patients admitted for COVID-19 and may precede AKI. Low levels of albuminuria suggest a predominant tubular origin, confirmed by the elevated levels of urine retinol binding protein. Urine protein-creatinine ratio ≥1 g/g at admission is strongly associated with poor kidney and patient outcome.
26
Blanco-Vargas, Andrea, Christian Fernando Ramírez-Sierra, Marcela Duarte Castañeda, Milena Beltrán-Villarraga, Luz Karime Medina-Córdoba, Alex Enrique Florido-Cuellar, Jairo Armando Cardona-Bedoya, María Claudia Campos-Pinilla, and Aura Marina Pedroza-Rodriguez. "A novel textile wastewater treatment using ligninolytic co-culture and photocatalysis with TiO2." Universitas Scientiarum 23, no. 3 (December 10, 2018): 437–64. http://dx.doi.org/10.11144/javeriana.sc23-3.antw.
Повний текст джерелаАнотація:
Textile industries produce effluent waste water that, if discharged, exerts a negative impact on the environment. Thus, it is necessary to design and implement novel waste water treatment solutions. A sequential treatment consisting of ligninolytic co-culture with the fungi Pleurotus ostreatus and Phanerochaete crhysosporium (secondary treatment) coupled to TiO2/UV photocatalysis (tertiary treatment) was evaluated in the laboratory in order to discolor, detoxify, and reuse textile effluent waste water in subsequent textile dyeing cycles. After 48 h of secondary treatment, upto 80 % of the color in the waste water was removed and its chemical and biochemical oxygen demands (COD, and BOD5) were abated in 92 % and 76 %, respectively. Laccase and MnP activities were central to color removal and COD and BOD5 abatement, exhibiting activity values of 410 U.L-1 and 1 428 U.L-1, respectively. Subjecting waste water samples to 12h of tertiary treatment led to an 86 % color removal and 73 % and 86 % COD and BOD5 abatement, respectively. The application of a sequential treatment for 18 h improved the effectiveness of the waste water treatment, resultingin 89 % of color removal, along with 81 % and 89 % COD and BOD5 abatement, respectively. With this sequential treatment a bacterial inactivation of 55 % was observed. TiO2 films were reused continuously during two consecutive treatment cycles without thermic reactivation. Removal percentages greater than 50 % were attained. Acute toxicity tests performed with untreated waste water led to a lethality level of 100 % at 50 % in Hydra attenuata and to a growth inhibition of 54 % at 50 % in Lactuca sativa. Whereas sequentially treated waste water excreted a 13 % lethality at 6.25 % and aninhibition of 12 % at 75 % for H. attenuata and L. sativa, respectively. Finally, sequentially treated waste water was reused on dyeing experiments in which 0.86 mg.g-1 adsorbed dye per g of fabric, that is equivalent to 80 % of dye adsorption.
27
Koca, S. S., Y. Pehlivan, S. Akar, S. Şenel, A. Avanoglu Guler, O. Sosyal, A. Yazici, et al. "AB0479 LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN AXIAL SPONDYLOARTHRITIS IS HIGHER: DATA FROM TURKBIO." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1266.3–1267. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3140.
Повний текст джерелаАнотація:
Background:Choosing the best treatment strategy for a patient is one of the most difficult issues in modern rheumatology, as there are various factors affecting drug therapy in chronic diseases, such as efficacy, safety, and compliance. Physicians take care of long-term retention rate and responses for discontinuation of candidate drug.Objectives:The purpose of this study to assess the drug survival of certolizumab pegol (CZP) in patients with axial spondyloarthritis (ax-SpA) and to identify the predictors and reasons for discontinuation.Methods:Data on patient characteristics, demographics, diagnosis, duration of disease, treatment and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of December 2020, 410 ax-SpA patients received CZP and were included. Kaplan Meier plot was used for drug survival analysis. Cox regression analysis was performed to evaluate the predictor associated with drug survival.Results:During the median 54 months follow-up, 92 (22.4%) patients discontinued the CZP treatment. The reasons for discontinuation: ineffectivity was 58.7% (n=54), adverse events was 6.5%, pregnancy was 3.3% and surgery was 4.3%. The baseline characteristics of patients continue with CZP and discontinuation due to ineffectiveness were shown in the Table 1. Patients who discontinued CZP had higher HAQ, BASFI and BASDAI values. Moreover, they were more co-treated with NSAIDs and csDMARDs. At the month 36, retention rate of CZP was 71.5% in patients with ax-SpA (Figure 1).Conclusion:Real life experience from this nationwide TURKBIO registry show higher long-term retention rate of CZP in ax-SpA. Higher baseline disease activity and functional limitation predict discontinuation of CZP. Adding NSAIDs and csDMARDs to the treatment of the patient with poor prognosis cannot increase retention rates.Figure 1Drug survival of CZP in patients with Ax-SpATable 1.Baseline characteristics of ax-SpA patients who continue and discontinue CZPAll patients (n=410)Continue to CZP (n=318)Discontinue to CZP* (n=54)pFemales, n (%)185 (49,7)157 (49,4)28 (51,9)0,736Age, years42 (34-49)41 (34-49)45 (34-54)0,064Symptom duration, years11 (7-17)11 (6-16)12 (8,5-20)0,054HLA-B27, n (%)150 (63,8)129 (64,5)21 (60)0,609Previous bDMARDs, n (%)Adalimumab54 (14,5)42 (13,2)12 (22,2)0,082Etanercept53 (14,2)40 (12,6)13 (24,1)0,025Golimumab11 (3)7 (2,2)4 (7,4)0,060Infliximab39 (10,5)35 (11)4 (7,4)0,425Co-treated drugs, n (%)NSAID206 (55,4)169 (53,1)37 (68,5)0,036Methotrexate35 (9,4)22 (6,9)13 (24,1)<0,001Sulphasalazine61 (16,4)40 (12,6)21 (38,9)<0,001Leflunomide5 (1,3)2 (0,6)3 (5,6)0,023ESH, mm/h21,5 (10-37)21 (10-37)23 (10-34)0,999CRP, mg/dl7 (3-20)7 (3-20)7 (3-22)0,727HAQ0,63 (0,25-0,94)0,5 (0,25-0,88)0,75 (0,38-1,25)0,009BASFI21 (7-45)20,5 (6-41)31 (13-58)0,011BASDAI30,5 (13-52)30 (12-50)43 (23-61,5)0,002ASDAS2,7 (1,8-3,7)2,7 (1,8-3,6)2,9 (2,3-4)0,062*Discontinue due to ineffectivity.References:[1]Iannone F, et al. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes? Clin Drug Investig. 2019;39(6):565-575.Disclosure of Interests:None declared.
28
PIPER, J. D. A., N. J. McARDLE, and Y. ALMASKERI. "Palaeomagnetic study of the Cairnsmoor of Fleet Granite and Criffel-Dalbeattie granodiorite contact aureoles: Caledonian tectonics of the Southern Uplands of Scotland and Devonian palaeogeography." Geological Magazine 144, no. 5 (June 19, 2007): 811–35. http://dx.doi.org/10.1017/s0016756807003536.
Повний текст джерелаАнотація:
The plutons of Cairnsmoor of Fleet (392±2 Ma) and Criffel-Dalbeattie (397±2 Ma, both mineral isochron ages) comprise two of four major post-tectonic granitic complexes emplaced into the Southern Uplands, an Ordovician–Silurian back-arc and foreland basin complex formed at the northern margin of the Iapetus Suture. To expand the palaeomagnetic record of the Southern Uplands we have studied palaeomagnetism and magnetic fabrics in traverses spanning contacts of these intrusions with host mudrocks. A uniform anisotropy of magnetic susceptibility (AMS) fabric across the Cairnsmoor of Fleet contact has been enhanced by recrystallization into hornfels near the contact and records a late Acadian regional stress operative during, or soon after, emplacement of the pluton in Middle Devonian times. Magnetization during slow cooling recorded a dual polarity (‘A’) remanence in granite and hornfels with mean direction D/I = 92/−2° (α95 = 6.5°) yielding a palaeopole (Q = 6) at 2°N, 265°E linked to cooling at c. 392 Ma. Subsidiary magnetizations are overprints imparted during Variscan tectonism (‘B’, D/I = 194/6°) and Jurassic rifting within the adjoining Irish Sea Basin (‘C’, c. 160–140 Ma, D/I = 172/−52°). The Criffel-Dalbeattie pluton has more complex AMS fabrics recording both deformation and emplacement effects. Hematite of secondary hydrothermal origin is a significant feature of the rock magnetic record in the aureole, which is otherwise dominated by paramagnetism. The granodiorite is more strongly magnetized than the country rocks, accounting for a positive aeromagnetic anomaly. A fairly dispersed dual polarity remanence (mean D/I = 115/55°, α95 = 18°) in granodiorite and late tectonic porphyrite dykes is probably the oldest magnetization preserved in this pluton because it correlates with an excursion of Britain into southerly palaeolatitudes at c. 410 Ma and indicates an Early Devonian emplacement age. The palaeofield at c. 397 Ma, the currently accepted isotopic age, is recorded by a minority overprinted remanence (mean D/I = 272/2°, α95 = 12°) similar to the record in the Cairnsmoor of Fleet pluton and granites from the adjoining Lake District terrane. Granite complexes of the Southern Uplands Block collectively record regional rotation and excursion of Britain into southerly latitudes between c. 410 and 390 Ma. Comparable Silurian–Devonian palaeomagnetic poles identify common apparent polar wander (APW) in paratectonic and orthotectonic terranes from the Variscan Front in the south to the Laurentian foreland in the north following climactic Acadian deformation. APW between 430 and 390 Ma embracing the (post-closure) history of the Caledonian orogen is a loop executed at rates much higher than typical rates of plate motion and appears to record a component of true polar wander. The ∼110° arc length is identical to polar shift identified between mid-Silurian and Lower–Middle Devonian poles from Gondwana. The two paths superimpose to show that the western margin of Gondwana was in proximity to the SE margin of Laurentia during Acadian deformation in Early–Middle Devonian times and remote from the Caledonides; the residual Rheic Ocean subsequently closed by a combination of pivotal and left lateral strike-slip motions.
29
Hora, Heinrich. "World Survey of Activities in Controlled Fusion Research, 1997 Edition, International Atomic Energy Agency, Vienna (1997), 410 pages, ISBN 92–0-104397-X, Nuclear Fusion, Volume 37, Special Supplement 1997, ISSN 0029–5515, Austrian shillings 450 (including delivery)." Laser and Particle Beams 16, no. 4 (December 1998): 649. http://dx.doi.org/10.1017/s0263034600011460.
Повний текст джерела
30
Abu-Amero, Khaled K., Carol A. Wyngaard, Olyan M. Al-Boudari, Marios Kambouris, and Nduna Dzimiri. "Lack of Association of Lipoprotein Lipase Gene Polymorphisms With Coronary Artery Disease in the Saudi Arab Population." Archives of Pathology & Laboratory Medicine 127, no. 5 (May 1, 2003): 597–600. http://dx.doi.org/10.5858/2003-127-0597-loaoll.
Повний текст джерелаАнотація:
Abstract Context.—Previous studies reported an association of certain polymorphisms in the lipoprotein lipase (LPL) gene with the risk of coronary artery disease (CAD); however, these studies were small and inconsistent. In addition, none of these studies attempted to establish such an association in the Arab population. Objective.—To determine whether 2 LPL polymorphisms (LPL-HindIII and LPL-PvuII located on introns 8 and 6, respectively, of the LPL gene) can be considered as independent risk factors or as predictors for CAD in Arabs. Design.—We used polymerase chain reaction and restriction enzyme digestion to determine the distribution of the LPL-HindIII and LPL-PvuII polymorphisms among healthy blood donors of Arabic origin (BD group) and angiographically confirmed CAD patients (CAD group) with identical ethnic backgrounds. Results.—For the HindIII genotypes, within the BD group (n = 410), the +/+ genotype was found in 206 individuals (50.2%), 173 (42.2%) carried the +/− genotype, and 31 (7.6%) carried the −/− genotype. Within the CAD group (n = 352), the +/+ genotype was found in 189 individuals (53.7%), 138 (39.2%) carried the +/− genotype, and 25 (7.1%) carried the −/− genotype. P values of .38, .45, and .92 were obtained for the +/+, +/−, and −/− genotypes, respectively. For the PvuII genotypes, within the BD group (n = 511), the +/+ genotype was found in 182 individuals (35.6%), 248 (48.5%) carried the +/− genotype, and 81 (15.9%) carried the −/− genotype. Within the CAD group (n = 431), the +/+ genotype was found in 138 individuals (32%), 225 (52.2%) carried the +/− genotype, and 68 (15.8%) carried the −/− genotype. P values of .28, .29, and .98 were obtained for the +/+, +/−, and −/− genotypes, respectively. The distribution and the allele frequency of these 2 LPL variants were similar in CAD and BD study groups and followed the Hardy-Weinberg equilibrium. Conclusion.—There was no difference in the distribution of both LPL polymorphisms between the healthy group and the CAD group. Therefore, these 2 LPL polymorphisms cannot be considered as independent risk factors or as predictors for CAD in this population.
31
Ibekwe, Abasiofiok, Lisa Durso, Thomas F. Ducey, Adelumola Oladeinde, Charlene R. Jackson, Jonathan G. Frye, Robert Dungan та ін. "Diversity of Plasmids and Genes Encoding Resistance to Extended-Spectrum β-Lactamase in Escherichia coli from Different Animal Sources". Microorganisms 9, № 5 (13 травня 2021): 1057. http://dx.doi.org/10.3390/microorganisms9051057.
Повний текст джерелаАнотація:
Antimicrobial resistance associated with the spread of plasmid-encoded extended-spectrum β-lactamase (ESBL) genes conferring resistance to third generation cephalosporins is increasing worldwide. However, data on the population of ESBL producing E. coli in different animal sources and their antimicrobial characteristics are limited. The purpose of this study was to investigate potential reservoirs of ESBL-encoded genes in E. coli isolated from swine, beef, dairy, and poultry collected from different regions of the United States using whole-genome sequencing (WGS). Three hundred isolates were typed into different phylogroups, characterized by BOX AIR-1 PCR and tested for resistance to antimicrobials. Of the 300 isolates, 59.7% were resistant to sulfisoxazole, 49.3% to tetracycline, 32.3% to cephalothin, 22.3% to ampicillin, 20% to streptomycin, 16% to ticarcillin; resistance to the remaining 12 antimicrobials was less than 10%. Phylogroups A and B1 were most prevalent with A (n = 92, 30%) and B1 (87 = 29%). A total of nine E. coli isolates were confirmed as ESBL producers by double-disk synergy testing and multidrug resistant (MDR) to at least three antimicrobial drug classes. Using WGS, significantly higher numbers of ESBL-E. coli were detected in swine and dairy manure than from any other animal sources, suggesting that these may be the primary animal sources for ESBL producing E. coli. These isolates carry plasmids, such as IncFIA(B), IncFII, IncX1, IncX4, IncQ1, CollRNAI, Col440I, and acquired ARGs aph(6)-Id, aph(3″)-Ib, aadA5, aph(3′)-Ia, blaCTX-M-15, blaTEM-1B, mphA, ermB, catA1, sul1, sul2, tetB, dfrA17. One of the E. coli isolates from swine with ST 410 was resistant to nine antibiotics and carried more than 28 virulence factors, and this ST has been shown to belong to an international high-risk clone. Our data suggests that ESBL producing E. coli are widely distributed in different animal sources, but swine and dairy cattle may be their main reservoir.
32
Kelley, Robin Kate, Aaron N. Chang, Esperanza Anguiano, Jimmy Hwang, Hubert J. Stoppler, Ryan M. McWhirter, Anna L. Parks, et al. "Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): LBA204. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.lba204.
Повний текст джерелаАнотація:
LBA204 Background: Noninvasive biomarkers are urgently needed in HCC. MicroRNA (miRNA) are small, noncoding RNA that regulate mRNA expression and are detectable in tumor tissue and extracellular compartments. miRNA signatures in blood specimens show association with HCC diagnosis but have not been explored as pharmacodynamic or predictive biomarkers. We present a pilot study to identify differentially expressed miRNA using NGS on serum from HCC patients at baseline and on targeted therapy, compared to controls. Methods: Serum samples were obtained from HCC patients enrolled on a clinical trial of sorafenib plus temsirolimus. Control sera were obtained from patients with non-malignant liver diseases (NMLD) and healthy volunteers (HV). Total RNA was extracted using RNAzol followed by library construction for each sample. Small RNA were separated by gel purification and sequenced by Illumina HiSeq 2500 at 5M+ reads per sample. Raw sequencing reads were mapped using Novoalign and quantified. Counts were normalized using an exogenous spike-in miRNA. Comparisons between HCC vs. control and baseline vs. on treatment cohorts were performed by linear regression (one-way ANOVA) and multiple-test corrected using Benjamini-Hochberg statistics. Candidate signature miRNA were derived using fold change, p-value, and abundance cutoffs. Results: Cohorts: HCC baseline (n=23) and paired on treatment (n=20), NMLD (n=12), and HV (n=10). HCC cohort: HBV+/dual 40%, HCV+ 32%. NMLD cohort: HCV+ 83%. Median RNA yield/200 µL was 410 ng (range: 69-1066) for HCC, 406 ng (range: 224-1100) for NMLD. The mapping rate ranged from 10-70%. Elevated AFP was associated with up-regulated miRNA identified in TCGA HCC cases, including miR-10a/b. No significant differences were observed for HBV+ vs. HCV+. Multiple oncomiRs appeared downregulated on treatment including Let-7 and miR-17/92 family members. Some miRNA isoforms were differentially regulated in each cohort. Conclusions: Serum miRNA in HCC patients demonstrate changes on treatment and can be characterized by NGS. Certain miRNA implicated in HCC appeared related to clinical covariates and warrant further study as novel biomarkers.
33
AlSaied, Ghiath, Hani Lababidi, Taher AlHawdar, Saud AlZahrani, Abdullah AlMotairi, and Mohamad AlMaani. "Outcome of Cancer Patients with an Unplanned Intensive Care Unit Admission: Predictors of Mortality and Long-term Survival." Saudi Journal of Medicine & Medical Sciences 12, no. 2 (April 2024): 153–61. http://dx.doi.org/10.4103/sjmms.sjmms_145_23.
Повний текст джерелаАнотація:
Abstract Background: Understanding the characteristics and outcomes of cancer patients with unplanned ICU admission is imperative for therapeutic decisions and prognostication purposes. Objective: To describe the clinical characteristics of patients with hematological and non-hematological malignancies (NHM) who require unplanned ICU admission and to determine the predictors of mortality and long-term survival. Methods: This retrospective study included all patients with cancer who had an unplanned ICU admission between 2011 and 2016 at a tertiary hospital in Saudi Arabia. The following variables were collected: age, gender, ICU length of stay (LOS), APACHE II score, type of malignancy, febrile neutropenia, source and time of admission, and need for mechanical ventilation (MV), renal replacement therapy (RRT), and treatment with vasopressors (VP). Predictors of mortality and survival rates at 28 days and 3, 6, and 12 months were calculated. Results: The study included 410 cancer patients with 466 unplanned ICU admissions. Of these, 52% had NHM. The average LOS in the ICU was 9.6 days and the mean APACHE score was 21.9. MV was needed in 73% of the patients, RRT in 15%, and VP in 24%, while febrile neutropenia was present in 24%. There were statistically significant differences between survivors and non-survivors in the APACHE II score (17.7 ± 8.0 vs. 25.6 ± 9.2), MV use (52% vs. 92%), need for RRT (6% vs. 23%), VP use (42% vs. 85%), and presence of febrile neutropenia (18% vs. 30%). The predictors of mortality were need for MV (OR = 4.97), VP (OR = 3.43), RRT (OR = 3.31), and APACHE II score (OR = 1.10). Survival rates at 28 days, 3, 6, and 12 months were 52%, 28%, 22%, and 15%, respectively. Conclusion: The survival rate of cancer patients with an unplanned admission to the ICU remains low. Predictors of mortality include need for MV, RRT, and VP and presence of febrile neutropenia. About 85% of cancer patients died within 1 year after ICU admission.
34
Cordeiro, Diogo, Zhiyuan Xu, Gautam U. Mehta, Dale Ding, Mary Lee Vance, Hideyuki Kano, Nathaniel Sisterson, et al. "Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study." Journal of Neurosurgery 131, no. 4 (October 2019): 1188–96. http://dx.doi.org/10.3171/2018.5.jns18509.
Повний текст джерелаАнотація:
OBJECTIVERecurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS.METHODSSeventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing’s disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6–246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism.RESULTSAt last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months.In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38).CONCLUSIONSHypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.
35
Shpakov, Alexey Vasilievich, Anton Anatolievich Artamonov, Andrey Vladimirivich Voronov, Evgeni V. Plotnikov, Alina Alexandrovna Puchkova, and Dmitry Olegovich Orlov. "Human Locomotion Strategies Under Changed Bodyweight Support." Aerospace Medicine and Human Performance 92, no. 1 (January 1, 2021): 4–10. http://dx.doi.org/10.3357/amhp.5609.2021.
Повний текст джерелаАнотація:
INTRODUCTION: The aim of this study was the analysis of human musculoskeletal system energy costs of normal walking and walking under reduced weight loading.METHODS: There were 15 subjects who participated in the study. We analyzed the biomechanical parameters of walking under different musculoskeletal system loads. The subjects walked on a treadmill at a pace of 90 steps/min under various loading conditions: 1) 100% bodyweight loading, corresponding to the terrestrial surface; 2) 38% bodyweight loading, corresponding to the surface of Mars; and 3) 17% bodyweight loading, corresponding to the surface of the Moon. Joint angles and angular velocities were recorded from the hip, knee, and ankle.RESULTS: We analyzed changes in joint phase trajectories and the ratio of kinetic extension energy to kinetic flexion energy in the joints. We observed changes in kinetic energy parameters associated with both flexion and extension motions in the joints of the feet while walking under various loads. In terrestrial conditions (walking under 100% bodyweight), flexion kinetic energy in the hip joint prevailed over extension kinetic energy by 90%, with a small variation equal to 22%. If weight loading decreased up to 17% (lunar conditions), the difference between flexion and extension kinetic energies diminished, and eventually reached only 9%. The ratio of flexion energy and extension energy in the ankle joint equalized under lower loading conditions. Thus, 38% bodyweight loading was sufficient for approximation of flexion and extension energy values.DISCUSSION: Our results revealed that phase trajectories shifted toward smaller joint angles and a decreased ratio between extension kinetic energy and flexion kinetic energy in the knee joint of all subjects. However, significant differences in the ratio of flexion and extension kinetic energy in the knee joint under bodyweight support were not found. The methods used for musculoskeletal system assessments that were proposed in our work can be used in clinical practice to evaluate the effectiveness of rehabilitation measures in a patients musculoskeletal system disorders.Shpakov AV, Artamonov AA, Voronov AV, Plotnikov EV, Puchkova AA, Orlov DO. Human locomotion strategies under changed bodyweight support. Aerosp Med Hum Perform. 2021; 92(1):410.
36
Smith, Mark C., James Kyle Russo, Chad Tracy, Darrion Mitchell, Sarah Mott, John Michael Buatti, and John Morgan Watkins. "Gleason <6 (G6) prostate cancer (PC) at radical prostatectomy (RP): Does a high-risk setting truly exist? A recursive partitioning analysis (RPA)." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 132. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.132.
Повний текст джерелаАнотація:
132 Background: G6PC is associated with low rates of PSA failure (bF) after primary treatment. The present study seeks to determine whether a "high-risk" subpopulation of G6PC with lower PSA relapse-free survival (bRFS) may be identified within a large population of men with mature follow-up who underwent RP for curative-intent. Methods: Patients were retrospectively identified for inclusion by cT1-2 PC with PSA <30 at diagnosis, managed by RP alone, with final pathology demonstrating G6PC. Exclusion criteria were: pT3b or pN1, pre- or post-RP (adjuvant) radiotherapy (RT) or hormone therapy, or PSA follow-up (<12 months). The Kaplan-Meier method was employed for survival probability estimation. RPA by conditional inference analysis was applied to identify variables associated with bF. Results: From 2003-2009, 284 patients were eligible for this analysis. The median age was 60 yrs (range, 44-76), 233 (82%) were T1c, and median PSA was 5.3 (92% <10 ng/dL). The median biopsy to RP interval was 50 days (11-410, with 97% <180 days). Eighty patients (28%) had a positive margin (M+). At a median follow-up of 92.6 months (16.9-160.9, with 45% followed >8 years), 32 patients (11%) had bF, with estimated 5/8yr bRFS rates of 91%/89%. Univariate analysis identified M+, EPE, detectable initial post-RP PSA (at <26wks post-RP), longer biopsy to RP interval, and smaller RP specimen volume as significantly associated with bF, with M+ and longer biopsy to RP interval significant at multivariate analysis. RPA identified only M+ as a stratification factor, with 5/8yr bRFS estimates of 79/74% for M+ vs. 96/95% for M-. No other factors permitted further substratification of risk. Of note, 7 of 12 patients who underwent salvage RT alone remained disease-free at last follow-up, including 7 of 8 whose highest pre-salvage RT PSA was <0.6. Conclusions: G6PC managed by RP alone is generally associated with high rates of bRFS; however, in the M+ setting, irrespective of other clinical factors, early bF rates >20% are observed. Adjuvant RT should be considered in G6PC M+ cases; however, close surveillance with early salvage RT may be a reasonable alternative.
37
Shimazu, Yutaka, Takeshi Maeda, Kenji Notohara, Takeshi Ito, Satoko Morita, Yayoi Fujiwara, Tatsuki Uchiyama, et al. "Diffuse Large B-Cell Lymphoma (DLBCL) with Central Nervous System (CNS) Relapse: Prognosis and Risk Factors by Retrospective Analysis from Single Center Experience." Blood 110, no. 11 (November 16, 2007): 3436. http://dx.doi.org/10.1182/blood.v110.11.3436.3436.
Повний текст джерелаАнотація:
Abstract Background: The introduction of rituximab into the therapy of DLBCL has improved the prognosis dramatically. However, relapse in CNS is still the issue. We studied the prognosis and risk factors of CNS recurrence in DLBCL. Method: Between Jan. 1996 and Apr. 2007, 441 patients were diagnosed to have DLBCL in our institute, of whom 31 patients were excluded due to CNS involvement at the time of initial diagnosis. We have analyzed 410 cases, in which 37 cases had relapsed in CNS. Before Sep. 2003, 168 patients were treated with the regimen based on CHOP, and after Sep. 2003, 242 patients were treated with the regimen based on CHOP plus rituximab. Once relapsing in CNS, the patients were treated with systemic chemotherapy plus high-dose methotrexate or radiation with intrathecal methotrexate. The risk category by the international prognostic index of these 411 cases was assessed as low: 36%, low-intermediate: 15%, high-intermediate: 23%, and high: 26%. Results: The median age was 71 years old (range: 17–92). Median follow-up period was 507 days, and the median period free from relapsing in CNS was 331 days. The mean survival period of the cases with CNS relapse, of the cases relapsed outside the CNS, and of the non-relapsed cases was 1328 days, 2290 days, and 2817days, respectively. The overall survival rate of cases with CNS relapse was significantly lower than that of the cases relapsed outside the CNS, or than that of the non-relapsed cases (p=0.0233, p=0.0003, respectively). Multivariate Cox regression analysis identified the increased lactate dehydrogenase (p=0.014), the involvement of more than one extranodal site (p=0.006), and not using rituximab before CNS relapse (p=0.040) as an independent predictor of CNS recurrence. Conclusion: CNS relapse has extremely poor prognosis than relapse outside the CNS in DLBCL. Rituximab may be effective in preventing CNS relapse. Since rituximab poorly penetrates into CNS, this may partly due to the reduction of all recurrence by rituximab. According to the risk assessment in CNS relapse, an effective CNS prophylaxis strategy should be determined.
38
Klein, E. A., S. M. Falzarano, T. Maddala, D. Cherbavaz, W. F. Novotny, C. Millward, and C. Magi-Galluzzi. "Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy." Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 36. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.36.
Повний текст джерелаАнотація:
36 Background: The association of TMPRSS2-ERG fusions and ERG expression in prostate cancer (PC) with adverse clinical outcomes has been controversial, with mixed results in the literature. We conducted a study to test whether tumor-derived gene expression profiles, including the presence of TMPRSS2-ERG fusions and ERG gene expression, are associated with clinical recurrence (cR) after radical prostatectomy (RP). Methods: All patients with clinical stage T1/T2 prostate cancer treated with RP at CC from 1987 to 2004 were identified (n∼f2,600). A cohort sampling design was used to select 127 patients with cR and 374 patients without cR after RP. For each patient a primary Gleason pattern (GP) sample, secondary (or highest) GP sample, and an adjacent nontumor tissue sample were evaluated. Surgical Gleason Score (GS) and clinical data were centrally reviewed. RNA was extracted from 6 manually dissected 10 μ m formalin-fixed paraffin-embedded sections obtained from RP specimens and expression of TMPRSS2-ERGa, TMPRSS2-ERGb, ERG and reference genes were quantified using RT-PCR. Times to cR, PSA recurrence, and PC death were analyzed using Cox PH regression. Results: Blocks from 441 patients were evaluable. Median F/U was 5.8 years. Patients were mostly Caucasian (83%), clinical stage T1 (66%), had baseline PSA <10 ng/mL (82%), and had surgical Gleason score ≤7 (87%). 848 tumor samples and 410 non-tumor samples were assessed. TMPRSS2-ERGa and/or TMPRSS2-ERGb fusions were present in 51.8% of tumor samples and 7.5% of non-tumor samples. There was 89% concordance (95% CI: 86%, 92%) for TMPRSS2-ERG fusion status between the 2 tumor samples for each patient. High ERG expression was strongly associated with the presence of TMPRSS2-ERG fusions (p <0.01). We did not find an association between TMPRSS2-ERG a/b gene rearrangement or ERG expression with cR, PSA recurrence, PC death, or surgical GS (p > 0.2). Conclusions: This study was notable for the large number of cR events, use of a standardized quantitative assay, and rigorous central review of pathology and clinical data. We did not find an association of TMPRSS2-ERG gene rearrangements or ERG expression with aggressiveness of prostate cancer post RP. [Table: see text]
39
Jevalikar, Ganesh, Rutuja Sharma, Khalid J. Farooqui, Anshu Singh, Sandeep Budhiraja, Arun Dewan, and Ambrish Mithal. "Lack of Association Between 25-Hydroxyvitamin D Level and Outcomes in Hospitalized Indian Patients With COVID-19." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A277—A278. http://dx.doi.org/10.1210/jendso/bvab048.563.
Повний текст джерелаАнотація:
Abstract Vitamin D deficiency (VDD) is thought to play a role in determining the outcomes of COVID-19. India has a high prevalence of VDD. We hypothesized that VDD as measured by serum 25-hydroxyvitamin D (25OHD) <20 ng/mL is associated with severe COVID-19 infection. Outcomes were assessed by the WHO ordinal scale for clinical improvement (OSCI)1, the need for oxygen therapy, admission to an intensive care unit (ICU), and inflammatory markers. The diagnosis of COVID-19 was proven by RT-PCR on the nasopharyngeal swab for SARS-CoV2. Serum 25OHD and PTH were measured in addition to the standard protocol for COVID-19. Clinical and laboratory data were extracted from electronic medical records and analyzed using SPSS v22.0. Patients with OSCI score < 5 were classified as mild and ≥5 as severe disease. The study was approved by the Institutional Ethics Committee. A total of 410 patients (127 females, 9 pediatric, 17 asymptomatic) were included with a median age of 54 years (6–92 years) with 272(66.3%) having at least one co-morbid condition, including diabetes (190, 46.3%) and hypertension (164,40%). Patients with VDD (197,48%) were significantly younger (46.7±17.1 vs. 57.8±14.7 years) and had lesser prevalence of diabetes and hypertension (39.1% vs 52.4%, 29.4% vs 49.5%). Proportion of severe cases (26,13.2% vs. 31,14.6%), mortality (4, 2% vs. 11, 5.2%), oxygen requirement (68,34.5% vs.92,43.4), ICU admission (29, 14.7% vs. 42, 19.8%), need for inotropes (7,3.6% vs.12,5.7%) was not significantly different between patients with VDD and those with normal 25OHD level. The proportion of severe cases was similar across all 25OHD categories. There was no significant correlation between 25OHD levels and outcome OSCI, inflammatory markers (CRP, IL-6, D-dimer, ferritin, LDH). PTH levels positively correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010) and LDH (r0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with cholecalciferol with a median dose of 60000 IU. The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, baseline levels of 25OHD did not determine the severe clinical outcomes of COVID-19 or levels of inflammatory markers. Treatment with cholecalciferol did not make any difference to the clinical outcomes of those with VDD. Reference:1WHO R&D Blueprint, novel Coronavirus. Retrieved from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
40
Cohen, Amy, Thomas Erwes, Dora Wiskirchen, and Jessica Abrantes-Figueiredo. "Assessment of the effects of rapid diagnostic biofire blood culture identification panel in hospitalized patients." Antimicrobial Stewardship & Healthcare Epidemiology 2, S1 (May 16, 2022): s44. http://dx.doi.org/10.1017/ash.2022.140.
Повний текст джерелаАнотація:
Background: Bloodstream infections (BSIs) have life-threatening consequences; they contribute to increased global morbidity and mortality, particularly in critically ill patients. Consequently, early implementation of effective antimicrobial therapy is crucial. Microbiology stewardship efforts, such as rapid diagnostic testing, streamline healthcare resources while also optimizing clinical outcomes. These outcomes include decreased mortality, fewer days of hospitalization, and more efficient time to appropriate anti-infective regimens. Biofire Blood Culture Identification (BCID) is a 2-stage multiplexed PCR system yielding multiple pathogen etiologies, as well as antimicrobial resistance genes. Results are published ~60 minutes after a blood-culture Gram stain turns positive. The purpose of this study was to assess the clinical impact of rapid diagnostic PCR testing, which was introduced at Saint Francis Hospital in March 2020. Methods: We conducted a single-center, retrospective observational chart review before and after implementation of Biofire BCID, surveying all positive cultures from December 2019 through June 2020. Medical records were more thoroughly reviewed for patients who met study inclusion criteria. The primary outcome of interest, time to appropriate antimicrobial therapy, included both days to targeted therapy in the setting of a probable pathogen, and days to antibiotic discontinuation in the case of a likely contaminant (nonpathogenic normal skin flora introduced into culture at the time of collection or processing). Secondary outcomes included in-hospital mortality (death during hospitalization), and inpatient length of stay (LOS). Wilcoxon rank-sum tests were used for primary outcomes and Fisher exact tests were used for secondary outcomes. Results: Among 643 patients with positive blood cultures, 410 (63.8%) met the criteria. In the study, 220 patients before the intervention and 190 patients after the intervention were reviewed. The difference in mean days to targeted therapy with a probable pathogen and days to antibiotic discontinuation with a likely contaminant were both observed at a significance level (3.62 vs 1.79, P Inpatient mortality rates were higher prior to launching Biofire BCID, but they were not statistically significant (15.5% vs 14.2 %; P = .782). The average LOS before and after implementation was 12.6 days (range, 2–92 days), and 10 days (range, 2–68 days), respectively. This parameter was also not statistically significant (P = .597). Conclusions: We detected a trend toward a significant reduction in time to appropriate antimicrobial therapy following the launch of Biofire BCID. Incorporation of molecular rapid diagnostics for BSI evaluation should be the standard of care in hospital settings.Funding: NoneDisclosures: None
41
van den Bent, M. J., S. Erridge, M. A. Vogelbaum, A. K. Nowak, M. Sanson, A. A. Brandes, W. Wick, et al. "PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion." Neuro-Oncology 21, Supplement_3 (August 2019): iii3. http://dx.doi.org/10.1093/neuonc/noz126.006.
Повний текст джерелаАнотація:
Abstract BACKGROUND The 1st interim analysis of the CATNON trial showed benefit from adjuvant (adj) temozolomide (TMZ) on overall survival (OS) but remained inconclusive about concurrent (conc) TMZ. A 2nd interim analysis was planned after 356 events. MATERIAL AND METHODS The 2x2 factorial design phase III CATNON trial randomized 751 adult patients with newly diagnosed non-codeleted anaplastic glioma to either 59.4 Gy radiotherapy (RT) alone; the same RT with concTMZ; the same RT and 12 cycles of adjTMZ or the same RT with both concTMZ and adjTMZ (doi: 10.1016/S0140-6736(17)31442-3). MGMT promoter methylation (MGMTmeth) status was re-assessed with the Infinium Methylation EPIC Beadchip using the MGMT_STP27 model. Isocitrate dehydrogenase 1 and 2 (IDH) mutation (mt) status was assessed with glioma targeted Agilent SureSelect baits sequence using an Illumina HiSeq2500 Rapid PE100. RESULTS With a median follow-up of 56 months and 356 events, the hazard ratio (HR) for OS adjusted for stratification factors after concTMZ was 0.968 (99.1% CI 0.73, 1.28). 5-year OS was 50.2% with and 52.7% without concTMZ (95% CI [44.4, 55.7] and [46.9, 58.1]). An IDHmt was found in 335 of 480 assessed cases (70%). Median OS was 19 mo (95% CI 16.3, 22.3) in IDHwt tumors and 116 mo (95% CI 82.0, 116.6) in IDHmt tumors. The interaction test based on IDH status was significant (p=0.016) in the univariate HR analysis for OS after concTMZ (IDHwt, n=145, events=120, HR = 1.27, 95% CI 0.89, 1.82, p=0.19; IDHmt, n=335, events=92, HR= 0.67, 95% CI 0.44, 1.03, p=0.06). IDHmt was predictive of benefit from adjTMZ (IDHmt HR: 0.41, 95% CI 0.27, 0.64; IDHwt: HR 1.05, 95% CI 0.73, 1.52; interaction test p = 0.001). In IDHmt patients that received adjTMZ, the HR for OS after concTMZ was 0.71 (95% CI 0.35, 1.42, p=0.32). MGMTmeth was found in 288 of 410 assessed cases (70%), interaction test for concTMZ (p = 0.092) and adjTMZ (p = 0.166) did not reach statistical significance. CONCLUSION In the entire study cohort, concTMZ did not increase OS. However, in IDHmt tumors a trend towards benefit of concTMZ is present. AdjTMZ increased OS in IDHmt but not in IDHwt tumors. Further analyses and follow-up will allow full assessment of efficacy in the molecular subgroups.
42
Tefferi, Ayalew, Kebede Begna, William J. Hogan, Mark R. Litzow, Curtis A. Hanson, and Animesh Pardanani. "Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis." Blood 118, no. 21 (November 18, 2011): 1752. http://dx.doi.org/10.1182/blood.v118.21.1752.1752.
Повний текст джерелаАнотація:
Abstract Abstract 1752 Background: Patients with primary (PMF) or post-polycythemia vera/essential thrombocythemia (post-PV/ET MF) myelofibrosis often harbor a JAK2 mutation and also display abnormally increased inflammatory cytokines (J Clin Oncol. 2011;29:1356). Therefore, JAK-STAT is an appealing drug target in such patients. Ruxolitinib (INCB018424) is a small molecule ATP mimetic that inhibits both JAK1 and JAK2 and has been evaluated for its therapeutic activity in MF, in the setting of phases 1, 2, and 3 clinical trials. Methods: The first phase-1/2 MF study using ruxolitinib was conducted at the MD Anderson Cancer Center and Mayo Clinic. A total of 153 patients were included in the study whose first line results were published in September, 2010 (NEJM 2010;363:1117). The current report constitutes a sponsor-independent analysis of long-term outcome in the 51 Mayo Clinic patients who participated in the particular clinical trial. Results I: Baseline characteristics: The 51 patients (37 males) from the Mayo Clinic were enrolled between October, 2007 and February 2009. The median time from treatment initiation is now 3.5 years. MF subtype distributions were PMF 60%, post-PV MF 32% and post-ET MF 10%. Median (range) values were age 61 years (39–79), hemoglobin 10.6 g/dL (7.4-15.3), leukocyte count 15.8 (2.0–136), and palpable spleen size 19 cm (0–32). The proportion of patients with red cell transfusion dependency was 24%, hemoglobin <10 g/dL 38%, unfavorable karyotype 18%, pruritus 24%, night sweats 26%, and JAK2V617F 84%. DIPSS-plus risk distributions were high 18%, intermediate-2 48%, intermediate-1 22% and low 14%. Results II: Response and treatment duration: According to the International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria, spleen response rate was 29% and anemia response rate 21%. Responses were also seen in constitutional symptoms (63%) and pruritus (92%). To date, treatment has been discontinued in 47 (92%) patients. The treatment discontinuation rates at 1, 2 and 3 years were 51%, 72% and 89%, respectively. For the 47 patients who were taken off study, median duration of treatment was 9.2 months (range 1.3–42 months). Reasons for treatment discontinuation included loss or lack of response/disease progression (∼40%), toxicity with and without lack of response/disease progression (∼34%), patient/physician choice often associated with lack of response (13%), and death on study (∼4%). Results III: Toxicity: Grade ≥2 thrombocytopenia and anemia occurred in 26% and 33% of patients and persisted in the majority of afflicted patients after drug discontinuation. To date, 18 deaths (36%) and 5 (10%) leukemic transformations have been recorded. Serious adverse events occurred upon drug discontinuation in 6 cases (13%) and were characterized by immediate relapse of symptoms, rapid and painful enlargement of spleen sometimes associated to splenic infarct, and acute hemodynamic decompensation occasionally leading to a septic shock-like syndrome. Results IV: Survival: There was no significant difference in the survival of the 51 ruxolitinib-treated patients compared to that of a cohort of 410 cases of PMF seen at the Mayo Clinic in the most recent 10-year period: unadjusted (Figure 1; p=0.43) and adjusted for DIPSS-plus (Figure 2; p=0.58). Conclusions: Ruxolitinib is effective in alleviating constitutional symptoms in the majority of patients with MF. Its activity in reducing spleen size is modest and not always durable. It is imperative that patients be alerted about important drug adverse events including potentially irreversible thrombocytopenia, worsening of anemia, and potentially catastrophic withdrawal symptoms. Ruxolitinib therapy does not appear to affect survival in MF. Disclosures: No relevant conflicts of interest to declare.
43
Bram Ednersson, Susanne, Mimmie Stern, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, Herman Nilsson-Ehle, Sverker Hasselblom, and Per-Ola Andersson. "Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype." Blood 134, Supplement_1 (November 13, 2019): 3967. http://dx.doi.org/10.1182/blood-2019-126387.
Повний текст джерелаАнотація:
Background: The cell-of-origin (COO) concept, based on gene expression profiling (GEP), dividing diffuse large B-cell lymphoma (DLBCL) patients into germinal center B cell (GCB) or activated B cell (ABC) subtypes, is a well-established subclassification where ABC patients have an inferior survival. The hallmark the ABC-type is constitutive activation of nuclear factor kappa B (NF-κB), often due to mutations in the B-cell receptor (BCR) signaling pathway. This has been the underlying rationale for adding newer drugs, such as bortezomib, ibrutinib or lenalidomide, to R-CHOP for ABC patients. However, none of these combinations studied in phase III trials have shown any clinical benefit. So, the complexity of ABC DLBCL is probably not only explained by genetic alterations and transcriptional changes as gene expression not necessarily correlate with protein expression, and protein action and dynamics are not caught by genomics-based techniques. Instead, using methods to measure global protein expression and interactions could offer new insights into the ABC subtype and possibly aid in the identification of novel drug targets. Aim: To study possible differences in global protein expression between ABC and GCB DLBCL subtypes using quantitative proteomics. Patients: A total of 213 adult DLBCL patients in western Sweden diagnosed between 1/1 2004 and 31/12 2016, were included. All patients received immunochemotherapy (R-CHOP). Primary mediastinal large B-cell lymphoma, primary CNS lymphoma, HIV-related lymphoma and transformed lymphoma were excluded. From archived formalin-fixed, paraffin-embedded (FFPE) tissue sections, from the time of diagnosis, a core biopsy (1 mm diameter) were obtained from each patient sample. Methods: COO was determined using the Hans immunohistochemistry algorithm. For 92 of the 213 patients, COO was also determined using the gene expression Lymph2cx chip: 14% changed subtype group from either non-GCB to GCB (n=8), GCB to ABC (n=4) or GCB to unclassified (n=1). From the FFPE samples a proteomic analysis was performed. In short, peptides were labelled using tandem mass tag (TMT) according to the manufacturer instructions and samples were analysed on an Orbitrap Fusion Tribrid mass spectrometer. The data files were merged for identification and relative quantification using Proteome Discoverer version 1.4.The search used the Human Swissprot Database version August 2016 using Mascot 2.3 as a search engine. The differentially expressed proteins were analysed using STRING version 10.0, for pathway analysis we used the Reactome database resource, and for potentially druggable proteins we used the Human Protein Atlas website which holds protein information of the current FDA approved drugs directed to 672 separate human proteins. Results: In all, 3078 proteins could be identified in all patients and 793 proteins were differentially expressed (p<0.05 adjusted for mass significance according to Benjamin-Hochberg) between ABC and GCB patients. Of these, 410 proteins were overexpressed in the ABC group. Among the most expressed proteins were several well-known ABC-associated proteins (such as IRF4/MUM1, HSP90B1, CCDC50 and STAT3) in addition to a large number of proteins previously not described in ABC DLBCL, e.g. neudesin, BLNK, MPST, BPGM, SUB1, SP140, PCK2, PARP4, SRP54, SRP68, SRP72, TRPV2, IGF2R and FGD2. A majority of the 410 proteins were closely linked with an enrichment p-value < 1x10-16(Fig. 1) and the most enriched pathways were immune system (FDR rate 3.3 x 10-27), interferon signaling (2.9 x 10-7), antigen processing (8.8 x 10-7) and down-modulation of cell surface receptors (4.7 x 10-5). Most interestingly, we also found that 16 proteins overexpressed in the ABC group could be potential drug targets for an FDA approved drug, e.g. high affinity immunoglobulin gamma Fc receptor I, CD47, HDAC2, ELANE and carbonic anhydrase 1. Conclusions: In this large proteomic study we found a number of overexpressed proteins in the ABC subtype, previously not described in DLBCL. Even though functional studies aimed at individual proteins and protein interactions to evaluate potential clinical effect are needed, our findings reveal novel proteins that could be potential druggable targets in ABC DLBCL patients. Figure 1 Disclosures Enblad: Kite/Gilead: Membership on an entity's Board of Directors or advisory committees. Mellqvist:Amgen, Janssen, Oncopeptides, Sanofi, Sandoz, Takeda: Honoraria. Andersson:Abbvie and Janssen: Membership on an entity's Board of Directors or advisory committees; Gilead, Janssen and Roche: Consultancy; Gilead: Research Funding.
44
Deorce, C. B., F. L. G. Leite, and B. Loureiro. "269 EFFECT OF DIFFERENT COLLECTION FREQUENCY INTERVALS ON THE QUALITY OF SEMEN OF FRENCH BULLDOGS." Reproduction, Fertility and Development 27, no. 1 (2015): 223. http://dx.doi.org/10.1071/rdv27n1ab269.
Повний текст джерелаАнотація:
Dogs produce fewer sperm than other species. Furthermore, for French Bulldogs, anatomical peculiarities, low libido, and increased sensitivity to stress could cause further reductions in sperm count. The objective was to compare effects of semen collection at 24- versus 48-h intervals on semen quality of French Bulldogs. Five purebred French Bulldogs, 19 to 48 months old, were subjected to 5 semen collections (24 h apart). After a 30-day rest, collections were repeated, but the interval between collections was 48 h. Semen was collected (all 3 fractions) by digital manipulation without female stimuli. Volume was measured in a 20-mL syringe. Sperm concentration was determined with a Neubauer counting chamber. Motility and vigor were evaluated with a coverslipped drop of semen on a slide (preheated to 37°C). Motility was expressed as a percentage of motile sperm, and vigor was classified on a scale of 1 to 5. Morphology was evaluated by the panoptic method; 100 cells were counted and results expressed as the percentage of normal or defective cells. Effects of collection interval were analysed using PROC MIXED of SAS (animal as subject and collection as a repeated measure), with collections 2 to 5 compared with collection 1 (using the DIFF option). For collection every 24 h, the third, fourth, and fifth sperm collections were lower than the first collection for volume (10.4 ± 1.1, 8.3 ± 1.1, 5.6 ± 1.1, 3.5 ± 1.1, 2.4 ± 1.1 mL), concentration (437 ± 24, 448 ± 24, 370 ± 24, 322 ± 27, 258 ± 31 ×106 sperm mL–1), vigor (4.6 ± 0.2, 4.2 ± 0.2, 3.6 ± 0.2, 3.7 ± 0.2, 3 ± 0.2), and morphologically normal sperm (82 ± 2.2, 83 ± 2.2, 72 ± 2.2, 68 ± 2.5, 66 ± 2.9%). However, when the interval was increased to 48 h, only the fourth and fifth collections were lower (P < 0.05) than the first for volume (11.8 ± 1.1, 10.2 ± 1.1, 8.8 ± 1.1, 6.6 ± 1.1, 2.5 ± 1.1 mL), concentration (447 ± 24, 410 ± 24, 407 ± 24, 322 ± 24, 241 ± 31 ×106 sperm mL–1), vigor (5 ± 0.2, 4.8 ± 0.2, 4.4 ± 0.2, 4.2 ± 0.2, 4 ± 0.2), and sperm with normal morphology (92 ± 2.2, 90 ± 2.2, 87 ± 2.2, 80 ± 2.2, 81 ± 2.9%). Motility decreased (P < 0.05) following the fourth collection at 24-h intervals and decreased (P < 0.05) after the third collection at 48-h intervals. With a 24-h interval, 4 dogs had <60% motility lower at the fifth collection, whereas only 2 dogs had motility <60% on the fifth collection at 48-h intervals. In conclusion, semen collected at 48-h intervals was of better quality than semen collected at 24-h intervals.
45
Perme, Ema, and Daniela Brečko. "Letni posvet Andragoškega društva Slovenije." Andragoška spoznanja 3, no. 2 (December 1, 1997): 91–92. http://dx.doi.org/10.4312/as.3.2.91-92.
Повний текст джерелаАнотація:
Letni posvet Andragoškega društva Slovenije je potekal 12. in 13. maja v Novi Gorici. Udeležilo se ga je 70 od 410 članov društva. Strokovni del srečanja je bil tokrat v celoti namenjen pripravam na Unescovo konferenco o izobraževanju odraslih, ki jo organizirajo vsakih 12 let. Tako bodo slovenski andragogi na konferenci, ki bo julija v Hamburgu, svetovni javnosti predstavili nove načine izobraževanja odraslih v Sloveniji, študijske krožke, učenje v lokalnih skupnostih. Veliko pozornosti so namenili tudi izboljšanju razmer in kakovosti izobraževanja odraslih, pa tudi uvajanju nove informacijske tehnologije za kvalitetno računalniško podprto izobraževanje odraslih.
46
Jordan, K. J., R. H. Lipson, N. A. McDonald та D. S. Yang. "The C 4Π—4Σ band system of ZrCl near 410 nm". Chemical Physics Letters 193, № 6 (червень 1992): 499–506. http://dx.doi.org/10.1016/0009-2614(92)85839-3.
Повний текст джерела
47
Carsote, Mara, Dana Terzea, Florina Vasilescu, Anca-Pati Cucu, Adrian Ciuche, and Claudiu Nistor. "Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management." Diagnostics 13, no. 16 (August 17, 2023): 2698. http://dx.doi.org/10.3390/diagnostics13162698.
Повний текст джерелаАнотація:
We aimed to overview the most recent data on sternal metastases from a multidisciplinary approach (diagnosis strategies, outcome, and histological reports). This narrative review based on a PubMed search (between January 2020 and 22 July 2023) using key words such as “sternal”, “manubrium”, and “metastasis” within the title and/or abstract only included original papers that specifically addressed secondary sternal spreading of cancer in adults, for a total of 48 original articles (14 studies and 34 single case reports). A prior unpublished case in point is also introduced (percutaneous incisional biopsy was used to address a 10 cm sternal tumour upon first admission on an apparently healthy male). The studies (n = 14) may be classified into one of three groups: studies addressing the incidence of bone metastases (including sternum) amid different primary cancers, such as prostate cancer (N = 122 with bone metastases, 83% of them with chest wall metastases), head and neck cancers (N = 3620, 0.8% with bone metastases, and 10.34% of this subgroup with sternum involvement); and glioblastoma (N = 92 with bone metastases, 37% of them with non-vertebral metastases, including the sternum); assessment cohorts, including breast cancer (N = 410; accuracy and sensitivity of PET/CT vs. bone scintigraphy is superior with concern to sternum spreading) and bone metastases of unknown origin (N = 83, including a subgroup with sternum metastases; some features of PET/CT help the differentiation with multiple myeloma); and cohorts with various therapeutic approaches, such as palliative arterial embolization (N = 10), thymic neuroendocrine neoplasia (1/5 detected with sternum metastases), survival rates for sternum metastases vs. non-sternum chest wall involvement (N = 87), oligo-metastatic (sternal) breast cancer (3 studies, N = 16 for all of them), oligo-metastatic head and neck cancer (N = 81), conformal radiotherapy (N = 24,215, including an analysis on sternum spreading), and EBRT followed by MR-HIFU (N = 6). Core data coming from the isolated case reports (N = 34) showed a female to male ratio of 1.6; the females’ ages were between 34 and 80 (mean of 57.28) and the males’ ages varied between 33 and 79 (average of 58.78) years. The originating tumour profile revealed that the most frequent types were mammary (N = 8, all females) and thyroid (N = 9, both women and men), followed by bladder (N = 3), lung (N = 2), and kidney (N = 2). There was also one case for each of the following: adenoid cystic carcinoma of the jaw, malignant melanoma, caecum MiNEN, a brain and an extracranial meningioma, tongue carcinoma, cholangiocarcinoma, osteosarcoma, and hepatocellular carcinoma. To our knowledge, this is the most complex and the largest analysis of prior published data within the time frame of our methods. These data open up new perspectives of this intricate, dynamic, and challenging domain of sternum metastases. Awareness is a mandatory factor since the patients may have a complex multidisciplinary medical and/or surgical background or they are admitted for the first time with this condition; thus, the convolute puzzle will start from this newly detected sternal lump. Abbreviations: N = number of patients; n = number of studies; PET/CT = positron emission tomography/computed tomography; EVRT = external beam radiotherapy; MR-HIFU = magnetic resonance-guided high-intensity focused ultrasound; MiNEN = mixed neuroendocrine-non-neuroendocrine tumour.
48
Cui, Qingping, Haesook Kim, Da-Cheng Zhou, Peter H. Wiernik, Martin S. Tallman, and Robert E. Gallagher. "Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL)." Blood 110, no. 11 (November 16, 2007): 3167. http://dx.doi.org/10.1182/blood.v110.11.3167.3167.
Повний текст джерелаАнотація:
Abstract The molecular changes responsible for the recurrence of APL after achieving complete remission are largely unknown. The Phase III trial E2491 provided a venue for investigating whether treatment type had an effect on the changes in gene expression that occur from PTx to Rel, since ¼ of patients were randomized to receive only chemotherapy (C-set patients), while ¾ of patients additionally received all-trans retinoic acid (ATRA) either during the induction and/or maintenance phases of treatment (A-set patients). High-quality, ethanol-stored RNA was available from matched PTx and Rel samples with ≥85% blasts from 3 C-set and 3 A-set patients, who had the following characteristics: Patient-Set PTx WBC FAB Class P-Rα Type PTx Mutations Rel Mutations Days on ATRA Days off ATRA 1-C 68.6 M3 V None Flt3ITD & D835 0 N/A 2-C 2.4 M3 S Flt3ITD & D835 Flt3ITD 0 N/A 3-C 0.4 M3v S Flt3ITD & D835 Flt3ITD 0 N/A 4-A 77.4 M3v V Flt3ITD PML-RARα 142 Maintenance 0 5-A 3.0 M3 L - - 365 Maintenance 344 6-A 10.9 M3 V PML PML 19 Induction 410 Gene expression analysis utilized the Affymetrix Human Genome U-133 Plus 2.0 chip. Of 54,613 gene probe sets (gps), 6220 gps for named genes with a mean value >100 for all samples and a ≥100 absolute difference between PTx and Rel values were selected for study. By unsupervised hierarchical cluster analysis, the overall samples segregated into 2 major groups, PTx or Rel with single exceptions. The PTx samples co-segregated into 2 groups according to the co-incident parameters of high WBC count and V-form PML-RARα (Patients 1,4,6 vs 2,3,5). Most notably, the Rel samples segregated by treatment type, C-set and A-set. In order to identify the gps most significantly contributory to differences between the C- and A-set gene expression profiles, we made two linked analyses. First, 575 gps were selected based on the criteria of an ≥1.5-fold difference, p <0.05, between the average expression level of each gps in the 3 relapse samples of the A-set vs the C-set. Second, we identified 92/575 genes with a statistically-significant fold-change (p ≤0.05, paired T-test) from PTx to Rel. After editing out redundant gps, 21 unique gene transcripts (ugt) were upregulated (Up) and 54 ugt were downregulated (Dn) from PTx to Rel. There was a high degree of concordance between the fold-difference values in the Rel samples and the fold-change values from PTx to Rel. Remarkably, for 19/21 Up ugt and 49/54 Dn ugt, the selection was based on greater change in A-set than C-set samples. Prominent among the selected A-set ugt were those affecting DNA repair/replication (Up: NPN; Dn: RAD17, RPA1, PARP1, MCM3) and signal transduction (Up: STAT3, IRAK3, LIMK2, GRB10; Dn, STS-1, CSNK2A1, PAK2, OPN3). These results indicate that the addition of ATRA to chemotherapy-based treatment of APL (all patients received 2 courses of consolidation chemotherapy) had a major impact on the gene expression profile at relapse, which further suggests that ATRA treatment made an important and unique contribution to the molecular progression process leading to relapse.
49
McConnell, Sean C., Darcy R. Denner, Ashley D. Sample, Anthony C. Restaino, Wilfredo Marin, and Jill L. O. de Jong. "Dichotomous Roles for Hdac1 Haploinsufficiency in T Cell Acute Lymphoblastic Leukemia (T-ALL)." Blood 124, no. 21 (December 6, 2014): 2219. http://dx.doi.org/10.1182/blood.v124.21.2219.2219.
Повний текст джерелаАнотація:
Abstract Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups from histones and non-histone proteins, thereby modifying the structure of chromatin and regulating gene expression. HDACs have frequently been found to be upregulated in solid tumors and in hematological malignancies, leading to clinical trials of HDAC inhibitors for the treatment of various cancers. Oncogenic effects of HDACs are thought to be mediated by the epigenetic silencing of tumor suppressors. However, understanding of the specific gene targets of individual HDACs is lacking. In order to elucidate the function of HDAC1 in a cancer model, we have performed experiments comparing T cell leukemias in hdac1 haploinsufficient zebrafish with leukemias in their wild type siblings. For our initial studies, we tested whether loss of one allele of the hdac1 gene (haploinsufficiency) would reduce the oncogenic effects of c-Myc, a potent oncogene, and protect against leukemia. We generated T cell lymphoblastic leukemia (T-ALL) in both hdac1+/- haploinsufficient and wild type zebrafish siblings by overexpressing murine c-Myc in T cells using a rag2 promoter. We then monitored the hdac1+/- and wild type fish for tumor incidence, latency, growth and overall survival. The tumor incidence rates and mean latencies were not significantly different for hdac1+/- and wild type tumors. However, we found significant differences in primary tumor growth between these genotypes. Tumor progression was significantly faster for hdac1+/- fish (p=0.001), with mean time to stage 3 tumor (>50% of the animal showing evidence of tumor dissemination) of 43.3 ± 10.1 days (mean ± S.D.) compared with 76.3 ± 9.2 days for wild type siblings. Furthermore, survival of hdac1+/- fish was significantly shorter (p<0.01) at 70.3 ± 36.2 days compared with wild type siblings at 129.2 ± 57.8 days. In contrast, progression of transplanted hdac1+/- tumors was slower compared with transplanted wild type tumors. Only 8.3% of transplanted hdac1+/- tumors had extended into the thymus and other organs by 21 days following intra-peritoneal injection into recipients. In contrast, 92% of the wild type tumors had evidence of widespread tumor dissemination by 21 days post-transplant. Several mechanisms were considered as potential contributing factors to these differences between the hdac +/- and wild type leukemias, including cell cycle differences, the effects of different tumor micro-environments, and differences in leukemia-initiating cell (LIC) frequencies. We did not find obvious differences in cell cycle parameters between genotypes. Also, we found no effect from different microenvironments of tumors following transplantation into either hdac1 +/- or wild type recipients. In contrast, we did find significant differences in leukemia-initiating cell frequencies between the genotypes (p<0.0001). The LIC frequency for hdac1 +/- tumors was measured at 1 in 410 compared with a higher LIC frequency of 1 in 30 for wild type tumors. In summary, our data provide support for dual roles of hdac1 in leukemogenesis. In this model, hdac1 has an initial protective role acting as an oncosuppressor, leading to more rapid tumor progression and decreased survival of animals with hdac1 +/- haploinsufficient tumors compared with wild type tumors. Interestingly, hdac1 also behaved as an oncogene, with decreased tumor progression following transplantation of hdac1 haploinsufficient tumors compared with wild type tumors. Our data indicate that caution is warranted regarding the use of HDAC inhibitors in treating hematologic malignancy, as this treatment could have unintended consequences, particularly during early stages of tumor development. Explaining these apparently contradictory roles of hdac1 in leukemogenesis is the focus of ongoing investigation, including gene expression studies and validation of targets. Disclosures No relevant conflicts of interest to declare.
50
Wang, Gary J., Keren Glinert, and David H. Henry. "A Retrospective Study On the Efficacy of Relative Dose Intensities of Non-Hodgkin's Lymphoma Treatments: Response to Chemotherapy and Overall Survival." Blood 114, no. 22 (November 20, 2009): 1388. http://dx.doi.org/10.1182/blood.v114.22.1388.1388.
Повний текст джерелаАнотація:
Abstract Abstract 1388 Poster Board I-410 Introduction: A common problem with chemotherapy treatments is reduced dose-intensities from treatment delays due to chemotherapy induced toxicities. In 2004, Lyman and colleagues assessed the overall incidence of reduced dose-intensities for 4,522 non-Hodgkin's lymphoma (NHL) patients. They determined that 53% of the patients, due to treatment delays of >7 days (24%) or reduced doses of >15% (40%), received a relative dose intensity (RDI) of <85% compared to NCCN standard dosage, with a mean RDI of 80.57% and a median of 86.48% (Lyman et al 2004 J Clin Onc). A similar study conducted by Lepage et al found 28% of 311 lymphoma patients were treated with <70% of the standard NCCN dose. These patients exhibited decreased chemotherapy response rates and shorter 2 year survival rates, with 61% surviving two or more years compared to 72% of patients getting >70% RDI (Lepage et al 1993 Annals Onc). In light of these studies, we conducted a retrospective chart analysis to assess the average RDI for NHL patients treated at our outpatient oncology clinic between 2006 and 2008, and determine if RDIs had a noticeable impact on patient responses to treatment. Methods: The primary objective of our chart review was to calculate the delivered dose intensities of chemotherapy for 60 NHL patients, and determine if a higher RDI resulted in better responses to chemotherapy and 2 year survival rates. We included only patients who received the 21-day cycle cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen, Rituximab-CHOP (R-CHOP) regimen, cyclophosphamide, vincristine, prednisone and rituximab (R-CVP) regimen, or the 14-day cycle R-CHOP regimen. Patients received between 3 and 8 cycles of chemotherapy over a period of 2 to 4 months. We calculated RDI by entering the dates of each cycle of chemotherapy, and the dose delivered of each drug in the regimen, into the Nearspace Inc. RDI calculator (http://www.nearspace.com/medical%2Dcalculator/rdi/). Any delays and/or reductions in the dosage (compared to the standard NCCN 21 or 14 day cycle CHOP/CVP regimen dosages) would result in a lower overall RDI. Results: Twelve (25%) of the 60 NHL patients received an RDI of less than 85%, and 5 patients (8.3%) received less than 70% of the standard NCCN dose. Nine patients (15%) received dose reductions of >15% and 10 patients (17%) had treatment delays of >7 days. The mean RDI was 91% and the median was 95%. There was minimal difference between the average RDIs for the treating regimens (CHOP = 91%, R-CHOP 14 = 91%, R-CHOP 21 = 91% and R-CVP = 88%). Patients over the age of 65 received an average RDI of 85% whereas patients under the age of 65 received an average RDI of 94%. Stage I patients (n=10, 16.7%) received an average RDI of 95%, stage II patients (n=11, 18.3%) received an average RDI of 90%, stage III patients (n=17, 28.5%) received an average RDI of 92%, and stage IV patients (n=22, 36.5%) received an average RDI of 87%. Forty-seven patients (78.3%) had a complete response to chemotherapy (average RDI = 92%), 4 patients (6.7%) exhibited a partial response (average RDI = 90.75%), 5 patients (8.3%) showed signs of stable disease (average RDI = 80.6%), and 4 patients (6.7%) had progressive disease (average RDI = 91%). The overall 2 year survival rate for all patients was 93.3%: the survival rate of patients with RDIs <85% and patients with RDIs >85% were both 93.3%. Conclusion: Both the mean and median RDI we found were higher than those found in the study by Lyman et al (91% and 95% respectively compared to 81% and 86%), and only 25% of patients received <85% RDI compared to 53% of patients in the study by Lyman and colleagues (Lyman et al 2004 J Clin Onc). The average RDI for our 60 patients was higher than that noted in previous studies (91% vs. 80.57% and 79%), and the overall 2 year survival rate was also correspondingly increased (93.3% vs. 61%) (Lepage et al 1993 Annals Onc; Lyman et al 2004 J Clin Onc). Our study is limited by its small sample size, and is inconclusive regarding whether a RDI of above or below the NCCN standard 85% does impact overall survival (both lower and higher RDI groups had a 93.33% survival rate). However we did find that fewer reduced doses and/or delayed treatments does in fact increase overall 2 year survival rates (93% compared to 72%, Lepage et al 1993) and had a positive impact on chemotherapy responses (87% exhibiting a complete response compared to 53%, Lyman et al 2004). Our study highlights the significance of limiting dose delays and reductions in chemotherapy regimens in order to improve patient responses. Disclosures: No relevant conflicts of interest to declare.